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ABSTRACT 
The purpose of this study is to demonstrate the ability of surface enhanced Raman 
scattering (SERS) active particles to enable multiplexed immunoassays in a lateral flow 
format for point of care (POC) testing. The SERS particles used for this study are chemically 
active glass coated gold particles, containing tracer molecules which in principle can be 
chosen to provide Raman Spectra with unique features allowing multiple tracers to be 
simultaneously measured and distinguished without interference between each other. 
Lateral flow immunoassay technology is the important part of this study and can be 
conveniently packaged for the use of other than highly skilled technicians outside of the 
laboratory. A well-known (single channel - simplex) device for the pregnancy test is a typical 
example of the lateral flow assay. Similar formats have been/are being developed by others 
for a range of POC applications – but most diagnostic applications require simultaneous 
determination of a range of biomarkers and multiplexed assays are difficult to achieve 
without significant interference between the individual assays. This is where SERS particles 
may provide some advantages over existing techniques. 
Cardiac markers are the growing market for point of care technology therefore biomarkers 
of cardiac injury (Troponin, myoglobin and CRP) have been chosen as a model. The object of 
the study is to establish the proof of concept multiplexing assay using these chosen 
biomarkers. Thus, initially all different particles were characterised in single and mixture 
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form. Also development of conjugate chemistry between antibodies for each analyte that 
have been purchased from commercial sources and SERS particles were analysed using 
different conditions like buffer, pH and antibody loading concentration to get the optimum 
intensity. The selected SERS particles and their conjugates were tested for size, aggregation 
and immune quality using a range of techniques: ultraviolet-visible (UV/Vis) absorption 
spectroscopy, dynamic light scattering (DLS) and lateral flow assay. These characterisations 
methodologies gave the understanding of optimum conditions of the each conjugates and 
individual’s behaviour in mixture conditions as well. 
After the characterisation all conjugates were tested singularly on the lateral flow assay 
using buffers and serum. The results of this single analyte immunoassay explained the 
individual’s bioactivity on the lateral flow strip. Further in study, multiplex assay have been 
demonstrated in serum. These outcomes have described each candidate characteristic in a 
mixture form on the lateral flow strip. In order to get the optimum Raman intensity from 
multiplex assay, the detection and capture antibodies loading concentrations were tuned in 
the assay. 
Later on different combinations (high, medium and low concentrations) of all three analytes 
were analysed and has found some interferences in multiplex assay. To investigate these 
issues various aspect were considered. First of all, different possibilities of non-specific 
interactions between the co-analytes and antibodies were tested. In addition, steric 
hindrance and optical interference investigations were performed via several assays and 
analysis using Scanning electron microscopy. The outcomes have confirmed related optical 
interferences. Therefore other assay (wound biomarkers) established to eliminate the 
interferences.  
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In summary, the works reported here have built and test the equipment and necessary 
reagents for individual assays before moving on the more complicated task. In addition, the 
entire study has given a deep knowledge of multiplex assay on a single test line including the 
investigation of the issues for selected cardiac biomarkers and their applications in the 
future. 
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CHAPTER 1: Introduction 
1.0 Background to point of care            
Point of care technology is often referred to as a quick, inexpensive, bedside detection 
technique for this there is a rapidly growing international market. POC technology is 
accomplished by the use of transportable, portable, and handheld instruments (e.g. 
homocystein and HIV tests, nerve conduction study device and blood glucose meter) Point 
of care testing has become established worldwide and finds a fundamental role in a public 
health (Tran and Kost, 2006). For early detection of human disease, biosensors form a major 
technology platform among POC techniques. Any biosensors that are based on 
immunoassay are presently extensively used in a range of areas, like research and 
development, clinical trials, diagnostics.(John et al., 2008). 
Lateral flow assay is the most extensively used technique to develop immunoassay 
biosensor devices. Currently most biosensor devices available on the market detect only a 
single analyte and employ optical or fluorescence-based detection that can be adversely 
affected by certain sample matrices, but there is a growing demand for biosensors to detect 
multiple analytes in complex mixtures (Brown and Doorn, 2008). 
Multiplexing in a biosensor platform represents a target for diagnosis testing: the ability to 
screen for more than one analyte at the same time, can lead to more precise diagnosis 
because the variation in the amount of few disease related analytes gives a more specific 
signature over the variation of a single marker. Multiplexing assays can also be applied in 
the post-diagnosis stage, where it can be valuable in following the patient to ensure therapy 
effectiveness (Collinson, 2000). 
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However, to detect multiple analytes requires one or more separation steps and/or multiple 
methods of detection to avoid signal interference or quenching. Various platforms have 
been developed for multiplexing detection. For example fluorescence-based systems, 
surface plasmon resonance (SPR) and gold Nano rods based system (Huang et al., 2012; 
Worsley et al., 2012; Wu et al., 2012) 
Surface enhanced Raman spectroscopy (SERS) is another approach for sensitive multiplexed 
detection from biological samples and of growing interest (Brown and Doorn, 2008; Wang et 
al., 2009) since it has the potential to achieve multiple analyte detection in one step 
reaction. 
1.1 Immunoassay 
Immunoassay is the most routinely used POC technique in many labs. ((a) Davies, 2005) In 
1977 Berson and Yellow was awarded the Noble prize in physiology and medicine for 
developing the first radioimmunoassay. This was the first time ever that an immunoassay 
was reported (Wu, 2006). An immunoassay system requires two key elements: 
1. The antibody raised against an analyte and 
2. A labeled analyte –analogue. 
The Principles of Immunoassay 
 
An immunoassay is a biochemical test that measures the presence of a given analyte in a 
sample. In the core of any immunoassay is the reaction of antigen (analyte) with the specific 
antibody, upon which an immunocomplex is formed (Figure 1.1). Either antibody or antigen 
has to be labeled so that a measurable signal can be generated that corresponds to analyte 
concentration. The label is responsible for the high sensitivity of the assay, while the 
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selectivity is achieved by the fact that antibodies possess high specificity and affinity for 
their antigens ((b) Davies, 2005) 
 
Figure 1.1: Formation of an immunocomplex – the core of immunoassay. 
 
Different formats of immunoassay are based on the antigen used in the system. Competitive 
or non-competitive assay /and homogeneous or heterogeneous assay. In the competitive 
immunoassay the unknown concentration of unlabeled analyte is mixed with a known 
amount of labeled analyte. The competition for the antibody binding site is initiated. The 
labeled analyte will bind to the antibody therefore the output signal is inversely 
proportional to analyte concentration ((b) Davies, 2005). In a non-competitive immunoassay 
this involves two antibodies, one on a solid phase (capture antibody) and second on a 
labeled reagent in solution (detection antibody). The analyte is bound between two highly 
specific antibodies and so this system referred as a ‘sandwich assay’. In this format with a 
higher concentration of the analyte, more labeled antibody will bind and so a greater signal 
will be produced. 
In heterogeneous assays, the portion of antigen bound with the antibody is disconnected 
from the remaining unbound part after the reaction takes place. This separation of assays is 
done via solid phase adsorption, liquid phase adsorption or precipitation. While on the 
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other side, in homogenous immunoassay the separation of immunocomplex is not required 
(Ullman, 2005). 
1.2 Lateral flow immunoassay  
An immunoassay is a simple biochemical test that measures the concentration of an analyte 
in a complex system like serum, saliva or urine using an antibody-antigen reaction. Lateral 
flows assays are a form of immunoassay often used for medical diagnostics also referred to 
as immunochromatographic assay. Lateral flow assays are simple procedures to detect the 
presence or absence of target analytes in a complex mixture and test kits have become 
popular in the clinical diagnostic field for biological samples such as hormones, antigens, 
toxins, drugs (Kim and Park, 2004). The commercially available pregnancy test kits are classic 
example of lateral flow immunoassay. (Osikowicz et al., 1990) 
A lateral flow assay is the important part of this study which is a form of “sandwich assay”. 
The main elements of lateral flow devices are: sample profilers pad, conjugate pad, 
nitrocellulose membrane containing specific capture antibody for the target analytes and an 
absorbance pad (Figure 1.2). The lateral flow test kit usually has an inlet for receiving a 
biological sample. After the complex sample (blood, serum, plasma or urine) is applied to 
the inlet, the sample flows from the sample pad through particles (eg. SERS active particles, 
gold particles, fluorescence particles labelled with detection antibody, etc.). Here they mix 
and the specific immunochemical reaction takes place. The liquid sample continues to 
transit through the nitrocellulose membrane towards the test line where capture antibodies 
are immobilised. Depending upon the analytes present in the sample the particles may react 
at the test line and generate what may be a visually distinguishable colour on the band. 
Excess liquid will continue to flow through the nitrocellulose towards a control line that 
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confirms the success of the assay by forming a colour band. The rest of the fluid continues 
to flow and can be collected in an absorbent pad. Thus, two bands are formed on the 
nitrocellulose, one of which is a test line for detection of the sample by its concentration 
and the other is the control line (Kim and Park, 2004). In order to detect multiple analytes, 
more than one test line can be used.  Lateral flow tests can operate in either competitive or 
sandwich assay formats. 
 
 
Figure 1.2: Schematic of typical lateral flow strip. 
 
1.3 Surface enhanced Raman spectroscopy (SERS) 
SERS is a surface sensitive technique. Discovered in 1970, it was shown that when small 
organic molecules, such as pyridine, adsorbed onto the surface of silver or gold, then the 
surface would exhibit 10 6- 10 14 enhancement of Raman scattering (Nie and Emory, 1997; 
Woo et al.,  2009). The exact mechanism of the enhancement effect of SERS is still not clear 
but two primary theories are involved: 
1. Electromagnetic theory arises from the presence of surface plasmons on the metal 
substrate. When a substrate is placed in the proximity of the Plasmon, it experiences an 
enhanced electromagnetic field and produces an enhanced scattered Raman field; and  
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2. Chemical theory that involves transfer of charge between the chemisorbed species and 
the metal surface. This enhancement is generally less than a factor of 10 (Stiles, 2008). 
1.3.1. The Raman Effect and normal Raman scattering 
When light is scattered from a molecule, most scattered photons have the same energy 
(frequency) as the incident photons. However, a small fraction of light (approximately 1 in 
107 photons) is scattered at optical frequencies different from, and usually lower than, the 
frequency of the incident photons. The process leading to this inelastic scatter is termed the 
Raman Effect. Raman scattering can occur with a change in vibrational, rotational or 
electronic energy of a molecule. The difference in energy between the incident photon and 
the Raman scattered photon is identical to the energy transferred to the scattering 
molecule. The energy of the vibration, rotational or other mode depends on the molecular 
structure and environment. Atomic mass, bond order, molecular geometry and hydrogen 
bonding all affect the vibrational force constant which, in turn dictates the vibrational 
energy (Stiles, 2008). 
SERS has enabled the sensitive detection of a variety of compounds of forensic, 
environmental or medical interest. The enhancement potentially enables detection of very 
low concentrations of biomolecules. The SERS technique also has the strong capability for 
multiplex targeting using individual or combinations of spectral signatures (Zavaleta et al., 
2009). SERS technology works in five steps: (1) laser light is shone on to a metal substrate; 
(2) plasmons are excited in the metal surface; (3) incident light is scattered by molecules 
absorbed on the metal surface; (4) Raman scattered light is transferred back to plasmons 
and scattered in air; and (5) plasmons at the metal surface act as antennae, which assist in 
coupling light into molecules close to the surface and couple out photons in specific 
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directions (Le Ru and Etchegoin, 2009). It is coupling into and out of the molecule that 
enhances the Raman signal (Figure 1.3).  
The plasmon response depends on the molecule’s structure and environment and the 
Raman spectra of different molecules are unique. Therefore SERS technologies leverage 
advantages like: 
1. Sensitivity due to metal enhancement of the Raman signal; 
2. Multiplex capability through the use of various dyes to produce tags with unique 
spectra (Bishnoi et al., 2011); 
3. Ability to detect and quantitate in complex mixtures, for example blood; 
4. Fast detection; 
5. Handheld instrumentation; 
6. Compatibility with lateral flow device manufacturer and calibration. 
These advantages and its highly specific nature, mean that Raman has become a very 
powerful tool for analysis and chemical monitoring (Baena and Lendl, 2004). Depending on 
the instrumentation, it can be a unique technique used for the analysis of solids, liquids and 
solutions and can even provide information on physical characteristics such as orientation or 
crystalline phase.  
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Figure 1.3: Schematic principle of surface enhanced Raman spectroscopy (SERS). When laser 
light scatters on the surface enhanced Raman scattering (SERS) molecule, signal 
enhancement arises via interaction of inelastic scattered light with surface plasmonas. 
 
1.3.2. SERS Particles 
Surface enhanced Raman scattering (SERS) active particles are developed by Oxonica Ltd 
and consist of a central gold core covered with a reporter molecule which is then 
encapsulated in silica to prevent the molecule from diffusing off the surface and, also, to 
avoid non-specific interactions of biological samples with the SERS active molecule (Figure 
1.4). 
To produce antibody conjugates the silica coating is chemically activated to enable specific 
attachment of an antibody to create a relevant bio-tag conjugate. Each of these Raman 
active particles gives a Raman spectrum dependent on the SERS reporter molecule. 
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Figure 1.4: Antibody conjugations with surface enhanced Raman scattering (SERS) active    
nanoparticle. The gold core is covered with a unique SERS reported molecule and then with 
a silica shell, which can be labelled with antibodies via chemical coupling to create a particle 
that specially interacts with the target analyte.  
 
 
1.3.3. SERS particles on lateral flow assay 
This study utilizes SERS active particles on lateral flow strips and uses Raman spectroscopy 
to detect the particles. Specific antibodies and target analytes were obtained from 
commercial suppliers. Techniques like enzyme linked immunosorbent assays (ELISA), 
dynamic light scattering (DLS) and UV-Vis spectroscopy were used to characterise the 
conjugate of the antibodies and SERS particles. This allowed for the identification of the 
bioactivity and stability of the conjugates. 
Lateral flow strip analyses are performed to detect multiple analytes by drying SERS active 
particles and antibodies on to the nitrocellulose strip. Parameters like blocking buffer effect 
capture antibody-loading concentration analysed for quality control analysis. Each analyte is 
detected singly over its pathological range using the lateral flow format. 
SERS based lateral flow immunoassay and quantitative optical detection technology 
provides these potential advantages over existing lateral flow assays currently on the 
market. 
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molecule 
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encapsulation 
  
gold core  
biorecognition 
(a) SERs active nanoparticle        (b) biomolecules 
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 Multiplexing capability by using different SERS active particles with different specific 
biological attachment. This will be used in a single test line in a sensitive lateral flow 
immunoassay format. Such an arrangement is not possible with other optical tags due to 
cross reaction or quenching of signals between different tags;  
 Leveraging of the performance of SERS active nano-particles to potentially increase 
sensitivity 1000 times over standard gold nano-particle bio-conjugates;  
 SERS active nano-particles have a convenient, glass/silica-encapsulated format that 
allows simple bio-functionalization with proteins and nucleic acids with near IR detection 
to minimize sample background interference. Devices can therefore be read in the 
presence of whole blood and other biological matrices. 
1.4 Selected target analytes  
Multiple analytes with a market need and clinical relevance in a POC test were identified in 
order to demonstrate multiplexed tests. Acute myocardial infarction (AMI) represent one of 
the major causes of premature death in the UK (35%) and is one of the cases where POC 
testing could provide better management leading to advantages for patients and the NHS. 
For this reason cardiac markers are one of the major growth areas for POC testing. 
(Collinson, 2000; Zhu et al., 2011) 
When heart muscle is damaged, cell walls break down, permitting proteins and enzymes, 
normally contained within the cell to leak into the bloodstream. These substances are called 
cardiac markers. They can be detected in blood samples with specialized immunoassays. For 
early detection of AMI, serum high-sensitivity cardiac troponin (hs-cTnI) and myoglobin 
(Myo) have been shown to be important biomarkers. (McCord et al., 2001; Plebani and 
Zaninotto, 1998)  
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This study has chosen the most common cardiac markers used in the evaluation of chest 
pain and acute myocardial infarctions that are troponin-I, myoglobin and C-reactive protein 
(CRP).  
1.4.1. Troponin I 
Troponin plays an important role in cardiovascular muscle contraction and regulation of 
skeletal muscle. Human cardiac troponin complex is 52kda. Troponin consists of three 
protein sub-units: troponin I (23kda), troponin T (35kda) and troponin c (18kda) which bind 
to the thin filament (actin) of striated muscle. Its major regulatory function is to bind 
calcium and regulate muscle contraction. Following injury to muscle cells (heart or skeletal 
muscles) the intact troponin complex along with free troponin subunits are released into 
blood (Thobhani et al., 2010; Perry, 1979). Although troponin is found in both skeletal 
muscles and the myocardium, the amino acid sequences for cardiac troponin T (cTnT) and I 
(cTnI) isoforms are significantly different from their skeletal muscle counterparts. 
Commercial assays have been constructed for measurement of cTnT and cTnI in blood that 
have been shown to have high specificity for cardiac disease. These assays are highly 
sensitive because the tissue concentrations of cardiac troponin T and I are higher than for 
other cardiac markers. The normal concentrations of these cardiac proteins are much lower 
than for myoglobin, CRP and CK-MB, as these proteins are also released from normal 
skeletal muscle turnover (de Winter et al., 1995). Cardiac troponin I is used as an aid in the 
diagnosis of myocardial infarction since its concentration becomes elevated in the blood 
approximately four to eight hours following myocardial injury or necrosis and remains 
elevated for several days (Ahammad et al., 2011). The pathological range of troponin I is 
0.05 – 30 ng/ml and the ‘cut-off’ (elevated level for cardiac infarction) is 0.4 ng/ml (Zhu et 
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al., 2011). Cut off levels are those concentrations accepted as thresholds at or above which 
the test is called positive as below which is called negative. Further in this study troponin I is 
identified as troponin in simple term. 
1.4.2. Myoglobin 
The second most important analyte is Myoglobin. Myoglobin is a protein (18 kDa) that 
transports oxygen in muscle tissue, including the myocardium and skeletal muscle. 
Myoglobin concentration in blood rises within one to two hours from the AMI occurrence 
(Mauro et al., 2005). It is a sensitive marker for muscle injury making it a potential marker 
for heart attack in patients with chest pain. Myoglobin as a cardiac marker, discharge quickly 
from the damage cell than other cardiac marker. This is an advantageous for earlier 
detection of AMI (Lewandrowski et al., 2002). The pathological range is 5 - 500 ng/ml with a 
cut off limit of 107 ng/ml (Penttila et al., 2002). 
1.4.3. C-Reactive protein 
C - reactive protein is found in the blood stream and the concentration rises in response to 
inflammation. In acute inflammation it rises above normal limits within six hours and peaks 
at eight hours. C - reactive protein is mainly associated with liver failure. In a recent study it 
was found that subjects with elevated levels of C-reactive protein were at increased risk of 
diabetes, hypertension and cardiovascular disease (Dehghan et al., 2007; Clearfield, 2005). A 
recent study shows that CRP is co-deposited with other activated complement within all 
acute myocardial infarcts (Lagrand et al., 1997; Algarra et al., 2013). Additionally, CRP peaks 
at the highest values at around 48 hours after the onset after myocardial infarction (Pepys 
and Hirsecfield, 2003; de Beer et al., 1982). Therefore this study has chosen C-reactive 
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protein as a third analyte for multiplexing assay. Pathological range of C-reactive protein is 
0.1 – 3 µg/ml with a cut off limit of 3 µg/ml (HyTest Ltd, 2013). 
1.5 Technology used for quality control analysis 
Different techniques like dynamic light scattering and Ultraviolet–visible spectroscopy used 
for SERS particles or conjugate characterisation analysis. 
1.5.1 DLS (Dynamic light scattering) 
Dynamic light scattering (DLS; sometimes referred to as photon correlation spectroscopy or 
quasi-elastic light scattering) is a technique for measuring the size of particles typically in the 
sub-micron region. DLS measures the scattering of light from particles in solution. As the 
intensity of the light scattered is proportional to the six power of the particle size, larger 
particles will give a greater signal than smaller particles. Thus a small percentage of 
aggregates will have a large intensity signal compared to a large proportion of small 
particles. A major advantage of the DLS technique is that samples can be quickly analysed in 
solution to determine whether the conjugates or the SERS itself single or in mixture are 
aggregated or not.  
1.5.2 UV-Vis (Ultraviolet–visible spectroscopy) 
Ultraviolet–visible spectroscopy (UV-Vis) refers to absorption spectroscopy or reflectance 
spectroscopy in the ultraviolet-visible spectral region. It uses light in the visible and adjacent 
(near-UV and near-infrared (NIR) ranges. The absorption or reflectance in the visible range 
directly affects the perceived colour of the chemicals involved. Molecules containing π-
electrons or non-bonding electrons (n-electrons) can absorb the energy in the form of 
ultraviolet or visible light to excite these electrons to higher anti-bonding molecular 
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orbitals. The more easily excited the electrons (i.e. lower energy gap between the HOMO 
and the LUMO) the higher the wavelength of light it can absorb. 
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CHAPTER 2: Materials and Methods 
2.0 Introduction 
This chapter will have a list of all the materials used in the whole study. It will then explain 
the method of antibody loading on the SERS particles and different techniques used for their 
characterisations. After that this chapter will conduct the establishment of the sample 
preparation for the single and mixture lateral flow strips using the capture antibody.  Finally 
the method of preparing, cutting and running a lateral flow assay will be demonstrated at 
the end. 
SERS instrumentation and Strips running techniques are also covered in this section. 
2.1 Materials 
Thiolated glass coated gold colloid particles (Au/glass) SERS 420, SERS 421, SERS 440 and 
SERS 470 were purchased from Becton Dickinson, (Chicago IL, USA). Rabbit anti-mouse 
antibody for the control line, human CRP free serum, human troponin, myoglobin and C-
reactive protein and their respective monoclonal antibodies (MAb) were obtained from 
HyTest Ltd (Turku, Finland). The heterobifunctional cross linker, succinimidyl 4-[N-
maleimidomethyl] cyclohexane-1-carboxylate (sulfo-SMCC), Tween 20 and 0.5 ml gel 
filtration columns were purchased from Thermo Scientific (United Kingdom). 
 Absolute ethanol and Parafilm M were purchased from Fisher Scientific (Loughborough, 
Leicestershire, UK). Anti-mouse IgG (whole molecule) antibody raised in rabbits was 
purchased from Sigma Aldrich (Poole, Dorset, UK). Other materials to prepare buffer and 
assist the conjugation process and lateral flow strip preparation were purchased from 
Sigma-Aldrich (Poole, Dorset, UK). Polyester backed nitrocellulose UniSart CN-140 (25 × 
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50m) was purchased from Whatman Ltd. (Maidstone, Kent, UK). Plastic backing cards 
(60 mm × 300 mm) for nitrocellulose mounting were purchased from BioDot Ltd. 
(Chichester, East Sussex, UK). 
Listed below are the buffers most commonly employed throughout the study. Water 
supplied from a Milli-Q Millipore ‘Advantage’ water purifier was used throughout.  
Conjugation Buffer: 50 mM borate at pH 6.5 for myoglobin and at pH 7.2 for troponin and 
CRP conjugations (pH adjusted by adding NaOH to boric acid solution.)  
Storage/suspension buffers prepared by adding 0.1 % BSA, 0.05 % Tween 20 and 0.05 % 
sodium azide to the respective conjugation buffer and pH adjusted to 6.5 or 7.2 accordingly. 
Coating buffer: 20 mM potassium phosphate, 2 % D-sorbitol, and 2 % ethanol, pH 7.4 
Running buffer:100 mM borate, 2 % BSA and 5 % Tween 20 pH 7.5. 
Buffers were supplemented with additional detergent (Tween 20) as required. All solutions 
were filtered through a 0.2 % filter prior to use. 
2.2 Conjugation of protein to SERS nanoparticles  
Monoclonal detection antibody (M19C7) anti-troponin (stock concentration 3.2 µg/ml) was 
diluted in borate buffer pH 7.2 to make up final concentration of 15 µg/ml. The diluted 
antibody solution was added into a fresh solution of sulfo-SMCC in water (2 mg/ml, 6.5 µl) 
and allowed to react 45 minutes. The final volume was 2.5 µl. borate buffer (40 µl) was 
added so as to make up 65 µl volume to use in filtration column. Unreacted cross linker was 
removed using micro bio-spin chromatography columns following the manufacturer’s 
directions using borate buffer (Thermo Scientific Pierce, 2013).  
The column’s bottom closure was removed and the column placed in 1.5-2.0 ml 
microcentrifuge collection tube and centrifuged at 1500 g for one minute to remove the 
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storage solution. The column was placed in new collection tube and 300 µl of buffer added 
and the column equilibrated. This step was repeated three times and the column placed in a 
new centrifuge tube. 30-130 µl of antibody solution was slowly applied to the centre of the 
compact resin bed and filter and centrifuged. Purified antibody was collected in centrifuge 
tube and desalting column was discarded after use.  
Purified and maleimide activated antibody solution was added into thiol activated SERS 
active nanoparticles (150 µl of stock; n.b. OD of stock was ≈ 0.25 at 540 nm at 100 fold 
dilution) solution. SERS particles –antibodies conjugates were prepared according to the 
scheme shown in Figure 2.1. This solution was left on a roller mixer (Stuart SRT6) three to 
four hours to react and finally the reaction between the modified antibody and the 
nanoparticles was quenched by addition of 2-mercaptoethanesulfonic acid sodium salt (1 
mg/100 µl, MESA). After quenching 45 minutes the conjugates were purified by centrifuging 
(5 min, 1000 RCF) on a micro centrifuge (Eppendorf). Supernatant was discarded and the 
pellet resuspended in resuspension buffer (215 µl; 20 mM borate buffer, 0.1% BSA, 0.05% 
Tween 20, 0.05% sodium azide). The centrifugation/resuspension step was repeated four 
times and finally the particles were resuspended in buffer (50 μl) and stored in a refrigerator 
prior to use.  
Monoclonal detection antibody (C6) anti-CRP conjugation with SERS nanoparticles was 
carried out using the same method and buffer as troponin conjugation. But for CRP antibody 
loading on SERS particles was 500 µg/ml. Monoclonal detection antibody (7C3) anti-
myoglobin conjugation with SERS nanoparticles was also carried out with the above 
conjugation procedure in borate buffer at pH 6.5 and the final antibody loading on particle 
was 270 µg/ml. Myoglobin conjugates were stored in suspension buffer at pH 6.5. 
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For optimisation of the conjugation method, each of the conjugate was prepared in four 
different buffers - sodium borate, sodium phosphate sodium acetate and PBS using three 
different pH 6.5, 7.2 and 7.5. Using the above method each conjugate was prepared and 
visually optimised for aggregation. Results are shown in the chapter 3. Optimised conjugates 
were used for the further study. 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 2.1: Reaction sequence for preparation of antibody–SERS particle conjugates. In the 
first step of conjugation, the NHS ester of sulfo-SMCC is reacted with lysine residues on the 
carrier protein, converting them to reactive maleimides that can react with thiolated SERS 
active particles and form antibody–SERS particle conjugates. 
2.3 Fabrication of lateral flow strip using of monoclonal antibodies  
MF4 and 560 capture monoclonal antibodies for troponin were purchase in stock 
concentration of 6 mg/ml and 12.6 mg/ml. From stock 1 mg/ml of MF4 and 560 were 
prepared in coating buffer and deposited on nitrocellulose strip CN140 using the Biodot 
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system. Thickness of test line is roughly 1.1 mm. Similarly, 1 mg/ml of 4E2 myoglobin 
capture antibody and 0.6 mg/ml of C2 antibody were used to prepare single analyte lateral 
flow strips for myoglobin and CRP assays. Troponin capture antibody 1 mg/ml, myoglobin 
capture antibody 1 mg/ml and 0.6 mg/ml CRP capture antibody were mixed in a tube with 
coating buffer prior speeding on the nitrocellulose for multiplexing assay. 
For the control line in a single and multiplex strip, rabbit anti-mouse antibody (1 mg/ml) was 
prepared from the stock of 3.4 mg/ml and loaded on each nitrocellulose strip at a distance 
of 4 – 5 mm from the test line. Each nitrocellulose strip was kept in the oven at 37 °C for half 
an hour. Each strip was mounted on a plastic backing card before cutting in 5 mm width 
using a biodot cutter (Biodot Ltd, U.K) and stored in separate boxes at 4 ◦C. 
2.4 Biodot system 
 A batch of lateral flow strip is prepared by Batch Dispense Workstation (XYZ 3050) and 
Cutting System (CM4000) supplied by Biodot. A batch Dispense Workstation (XYZ 3050) 
contains Dispense Ranges: Frontline, Biojet and Airjet. Frontline has minimum line width of 
0.33 mm, BioJet spray 20 nL - 2 µL/cm while AirJet spray 1 µL/cm - 22 µL/cm. It has a 
dispensed area of 450 × 70 mm. All dispensing is controlled by a handheld controller. The 
cutting system (CM4000) has safety interlock device as well. 
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Figure 2.2: Batch Dispense Workstation (XYZ 3050) for preparing lateral flow strips and 
Cutting System (CM4000) for cutting strips 
2.5 Sample preparation and lateral flow assay running method 
100 ng/ml troponin was prepared from troponin stock (heart complex) 1000 ng/ml in 50 µl 
of CRP free serum. Similarly 1000 ng/ml myoglobin was prepared from stock of 1mg/ml and 
10 µg/ml of CRP was prepared from 100 µg/ml of stock. Stock aliquots were frozen at -80°c. 
For the single assay each analyte was prepared in a serial dilution in eppendorf tubes using 
CRP free serum. 1 µl of each conjugate was added in respective analyte dilution and mixed 
well before running on the lateral flow strip. 
 While for the multiplex assay the  top concentration of each analyte (50 ng/ml for troponin, 
500 ng/ml myoglobin and 5 µg/ml CRP) was prepared in 50 µl CRP free serum. Serial 
dilutions were performed. The initial multiplexing assay was performed using an equal 
mixture of conjugate (5 µl of each conjugates) were mixed and 1 µl of this mixture was used 
in the assay (Results are in chapter 4 sections 4.1). Further in multiplexing myoglobin and 
troponin conjugate addition was altered by increasing their volume. 5µl CRP conjugate and 
7.5 µl of myoglobin and troponin conjugate were mixed in separate tube. Total 20 µl of 
conjugates having ratio of 1:1.5:1.5. In each dilution 1ul of conjugate mixture was added.   
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2.6 SERS particles  
Four different SERS active particles were identified for the study. Each particle is 
differentiated by the nature of the SERS reporter molecule immobilised on the gold core. 
The particles were selected on the basis of the spectral features unique to the reporter - 
thus enabling the particles to be differentiated from each other (Figure 2.3). 
Figure 2.3: SERS active molecules identified for use in this study. Product name is shown         
beneath each molecule.  
  
2.7 SERS instrumentation 
The Raman System R-3000 QE (Ocean Optics, Dunedin, USA; Figure 2.4) instrument is a 
partially integrated analyser for real-time quantitative and qualitative analysis of aqueous 
solutions, powders, tablets, gels and surface media. It includes a CCD-array spectrometer 
with a wavelength range of ~200-2700 cm-1 and 785 nm (red) solid-state diode lasers. The 
probe head coupling the sample to the spectrometer and laser is a flexible fibre optic cable 
(100 µm diameter and with one-meter length). Fibres are protected with stainless steel 
N N N N
D D D D
DDD D
N
N
N N
SERS 420 SERS 421 
SERS 440 SERS 470 
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sheathing. The stainless steel sampling tube is 3.5 inches long and 1/2 inch in diameter. 
There are two focusing caps: one focuses the laser beam on solid samples as the cap is 
pressed against the sample on lateral flow strip. The other focuses the laser on the inside of 
transparent containers containing liquids or gels when the cap is pressed against the outside 
wall of the container. To measure liquid sample liquid cap was used. Additionally, for 
instrument calibration acetonitrile was used this allowed for quick, software-controlled 
instrument calibration and verification.  
 
 
Figure 2.4: Raman spectrometer system with interlock. 
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Figure 2.5 Ocean Optics reader assembles with black safety box and interlock system. 
Internal view of black box that contains three-stage controller, laser probe and strip holder. 
A: Stage controllers (x, y and z control)   
B: Fibre optic probe 100-micron focal point 4.6 mm focal length 
C: Strip holder on x, y and z stage (± 40 nm resolution) 
 
The laser beam emerging from the R-3000 laser output port or from the fiber optic probe is 
a Class 3b laser. This laser product produces visible and/or uv laser radiation capable of 
causing serious eye injury and blindness to anyone who looks directly into the beam or its 
specular reflection. Therefore some modifications were done for the safety purpose. A black 
box with an interlock system was built (Figure 2.4). The box door was connected with 
magnetic interlock. So, when the door is open the shutter is shut down. In order to hold the 
lateral flow strip and measure via probe a strip holder was designed, built and fixed to an x, 
y and z stage controller controlled via software computer (Figure 2.5). Also the laser probe 
was fixed to the stage inside the black box. Lateral flow strips were cut in a fixed size and 
held by the strip holder at the same position every time. The laser scanning mode could be 
A 
B 
C 
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adjusted by control software (RSI, Renishow). Two different scanning procedures were 
evaluated using SERS nanoparticles strips. SERS particles are diluted 2, 4,8,16 and 64 fold in 
eppendorf tubes and then spread on the lateral flow strip using a biodot system. All strips 
were scanned by the Raman reader using two methods. The first scanning method scanning 
was 3 different positions on a test line and each point was exposed 30s by laser and 
collected data. The 2nd way of strip scanning was 3times across Y-axis at 37 mm/s. linear 
cam can scan 1.1 mm test line with constant velocity. This can cover only a small 
background and whole test line across y axis. Data was collected in csv format and peak 
height and peak area were analysed by Ranishow software .Results are shown in chapter 3 
(section 3.3). 
 
Figure 2.6: 1st strip is scanning three points on a test line. And 2nd strip is scanning Y axis 
(from bottom to top of the test line) at 37 mm/s using linear cam. 
 
2.8 DLS (Dynamic light scattering)  
Measurements were performed on the SERS particles to confirm the size of each particle 
and visualize the aggregation in buffer. Also SERS conjugates measurements were 
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performed to optimise different pH and varying protein-loading concentrations. All light 
scattering measurements were carried out using a Zetasizer Nano ZS (Malvern DTS 5.1). The 
viscosity of the sample was assumed to be the viscosity of the dispersant. Measurements 
were carried out at 25 C in disposable cuvettes using a sample volume of 100 l. Each 
sample was diluted 10 fold and measured in triplicate and the mean value reported. The 
wavelength of the HeNe laser used in the DLS instrument was 633 nm.  
2.9 UV-Vis (Ultraviolet – visible spectroscopy) 
UV-Vis measurements were carried out using a Lambda 850 spectrophotometer (Perkin 
Elmer) using a standard 1 cm path length quartz cuvette from Optiglass Ltd (Essex, UK). The 
reference beam sample was water or appropriate buffer. Spectra were obtained from 200 
to 800 nm (spectral resolution 1 nm), with the lamp change occurring at 319.2 nm. Milli-Q 
water was used as the blank for SERS particles and conjugate buffer used for the 
conjugation reactions. SERS nanoparticle solutions were monitored for both conjugation 
and aggregation by measuring SERS solution with: no antibody, immediately after addition 
of the antibody, at the end of the reaction and after centrifugation and re-suspension of the 
conjugates in storage buffer. Absorbance spectra were measured for each nanoparticle and 
their respective antibody-conjugates between the wavelengths of 800 nm to 200 nm. UV-Vis 
measurements can be used to indicate adsorption of proteins onto SERS with a change in 
absorbance peak for the nanoparticle. 
2.10 Two run assay 
In order to find steric hindrance in the assay two run assays was designed where first 
sample will run and then second sample will apply on the strip so if the first sample is 
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blocking the sights on the test line it will not allow binding of the second analyte from the 
second run. Multiplexing strips with troponin, myoglobin and CRP capture antibody strips 
were used for the assay. Troponin was used as model. Therefore run 1 was either CRP OR 
Myoglobin. Therefore for run 1, CRP 11l (9900 ng/ml) mixed with 22l of serum and 3.3l 
of sample buffer were mixed with 1.1l of CRP conjugates or without conjugates were 
adjusted by 4.4 l of buffer and run on the strip. Similarly myoglobin (1620 ng/ml) was 
mixed with 22l serum and 3.3 l buffers as mention above.  For run 2 troponin (150 ng/ml) 
was mixed with 22l of serum, 1.65 l of troponin conjugate and 2.75 l of sample buffer. 
Sample buffer was adjusted to keep the loading volume the same in each assay. 
 
Figure 2.7: In run 1 first analyte or buffer is running single form then in run 2 another 
analyte will be run on the same strip. Here CRP and myoglobin effect on troponin is 
analysed and troponin is run most of the time as a run 2.  
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2.11 Effect of high, medium and low concentration of analytes in 
multiplexing 
To investigate high, medium and low effect of each analytes on others candidates, three 
concentrations were selected for each. Table 2.1 and 2.2 represent the selected 
concentration of respective analytes. Multiplexing strips were prepared as mentioned in 
section 2.5.  Total twenty seven strips were run in duplicates for this assay.  Sample volume 
and sample running method was kept the same as previously mention in section 2.5. 
Table 2.1: High, medium and low concentration of all three candidates. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Analyte High(ng/ml) Medium(ng/ml) Low(ng/ml) 
CRP  1800 200 21 
cTnI 50 5 0.54 
Myo 178 30 6.5 
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Table 2.2: CRP, troponin and myoglobin concentration in each strip. 
 
Strip No CRP Myoglobin Troponin 
1 High High High 
2 High High Medium 
3 High High Low 
4 High Medium High 
5 High Medium Medium 
6 High Medium Low 
7 High low High 
8 High low Medium 
9 High low Low 
10 Medium High High 
11 Medium High Medium 
12 Medium High Low 
13 Medium Medium High 
14 Medium Medium Medium 
15 Medium Medium Low 
16 Medium low High 
17 Medium low Medium 
18 Medium low Low 
19 low High High 
20 low High Medium 
21 low High Low 
22 low Medium High 
23 low Medium Medium 
24 low Medium Low 
25 low low High 
26 low low Medium 
27 low low Low 
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CHAPTER 3: Calibration and characterisation  
3.0 Introduction 
The purpose of this study was to explore the use of surface enhanced Raman scattering 
(SERS) particles in an immunoassay for developing an innovative concept of multiple analyte 
detection on a single test strip. This chapter was aimed at: (1) characterisation and selection 
of the SERS particles for multiplex measurements; (2) development of the laser scanning 
procedure for reading the Raman signal from the SERS particles on the test line of lateral 
flow strips; (3) preparation and evaluation of SERS particle - antibody conjugates and (4) 
development of simplex lateral flow assays using each of the three selected analytes - 
troponin, myoglobin and CRP. Each of these is described in detail below. 
(1) Characterisation and selection of the SERS particles for multiplex measurements:  
Numerous studies have shown that the multiple characterisation techniques are required 
for the development of good-quality immunoassay conjugates to achieve enhanced 
performance of the diagnostic test (O’Farrell, 2009; Thobhani et al., 2010). Therefore, 
various characterisation techniques such as Raman analysis, UV-visible (UV/Vis) absorption 
spectroscopy, dynamic light scattering (DLS), were used to determine the extent of SERS 
particles’ nature, aggregation, size, shape, stability in different media and activity of the 
biological molecule (antibody) on their surfaces.  
Four SERS particles labelled with 420, 421, 440 and 470 reporters (structure of these 
reporter molecules is shown previously in Figure 2.3) were purchased from Oxonica. Raman 
spectrum of each SERS particles (420, 421, 440 and 470) was collected by a Raman reader. 
All Raman spectra were overlaid to identify a unique Raman peak for each SERS particle. 
This unique Raman peak was then used as the signature for identifying a particular SERS 
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particle. Additionally, two different combinations of three SERS particles were prepared to 
identify the combination giving the best well-separated unique Raman peaks (section 3.1).  
A calibration analysis was carried out to determine the relationship between the Raman 
intensity and concentration of each SERS particle in a suspension (section 3.2). UV-Vis 
analysis and DLS were used to measure the surface absorbance spectra, concentration, 
aggregation and size in single and mixture form of the SERS particles (section 3.4 and 3.5).  
(2) Development of the laser scanning procedure for reading signal from the SERS particles 
on test line of lateral flow strips: 
The Raman system R-3000 QE infra-red laser (Ocean Optics, Dunedin, USA) is commonly 
used in surface studies. This Raman system was chosen for this study because its laser 
frequency (785 nm) has little background interference from the blood-based samples, whilst 
providing a reasonable Raman signal. This laser was mounted onto a specially configured 
lateral flow stage holder and was operated with an interlock for safety reasons. The system 
was controlled using a Ranishow software to read the Raman spectra of SERS particles 
mounted on the lateral flow strip. A precise, stable, fast and reproducible technique of 
scanning the lateral flow strip to achieve maximum Raman intensity signal from a wider 
range of concentration of single and mixed particles bound on test line was developed after 
the modification of the purchased instrument.  Two different scanning methods were tested 
by the Raman reader. The first method was to scan at three different positions on a test 
line, with 30 s laser exposure at every position. The second method was to scan the Y-axis 
three times, from bottom to top of the test line (1.1 mm scan), at a constant velocity (37 
mm/s). SERS 420 particles were used as a model for this test. The Raman peak height and 
area were measured to choose the best scanning method for single and multiplex lateral 
flow research (section 3.3).  
31 
(3) Preparation and evaluation of SERS particle - antibody conjugates: 
Background research have shown that the development of a good quality antibody labelling 
technique is essential to achieve maximum bioactivity in the immunoassay (Aubin-Tam and 
Hamad, 2008; Chun, 2009). Therefore, the aim of this examination was to prepare high 
quality and stable protein-SERS particles conjugates without any aggregation. To accomplish 
this several parameters such as: the molarity of the salt in reaction buffer, the pH of the 
reaction, the concentration of antibody loaded onto the particles, and antibody–crosslinker 
(sulfo - SMCC) ratio, were optimised.   
The protocol of the manufacturer of crosslinker (sulfo - SMCC) suggested that the buffer 
selection should be made by avoiding buffers containing primary amines (e.g., Tris or 
glycine) and sulfhydryl during conjugation, because they can compete with the intended 
reaction. A pH below 7.5 for the maleimide group stability and the ratio of protein to 
crosslinker (5 - 80 - fold molar excess) were also recommended by the manufacturer’s protocol 
(Thermo Scientific Pierce, 2013).  Therefore, to obtain ideal conditions, individual SERS – 
detection antibody conjugates were prepared in different buffer and pH conditions and 
were optimised for aggregation first visually in solution, and then on the lateral flow strip. 
Similarly, antibody loading on SERS particles and antibody–cross-linker (sulfo - SMCC) ratio 
were also optimised (section 3.6).  
(4) Development of simplex lateral flow assays using each of the three selected analytes - 
troponin, myoglobin and CRP: 
Each biomarker was individually analysed on a single lateral flow strip using the conditions 
optimised in section 3.6, prior to moving on the complex system (mixture assay) to 
understand its performance and behaviour. Dose response curve were conducted for, 
troponin labelled to the 470 SERS particles, myoglobin labelled to the 440 SERS particles and 
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CRP labelled to the 421 SERS particles using analyte concentration proximate to their 
dynamic range in buffer and serum ( section 3.7 and 3.8). This experiment was conducted to 
identify the individual measurable range of each biomarker with the SERS detection 
technique. 
3.1 Spectra for various SERS  
Raman spectra of suspensions of each SERS particle are shown in Figure 3.1 and the spectra 
are overlaid in Figure 3.2 so that the unique peaks selection for each particle could be 
clearly identified. 
Figure 3.1: Raman spectra of the four selected SERS nanoparticles. SERS particle: (top left) 
420; (top right) 421; (bottom left) 470; and (bottom right) 440.  
600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800
0
5000
10000
15000
20000
25000
3
7
6
.1
9
1
9
8
5
1
.1
5
1
4
1
0
2
5
.7
5
4
6
1
0
7
7
.2
0
4
1
2
3
1
.6
6
0
6
1
2
9
9
.5
7
4
1
6
1
7
.5
8
5
6
In
te
n
s
it
y
  
  
  
 
Raman shift(cm-1)
 420
600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800
0
5000
10000
15000
20000
25000
30000
35000
40000
3
3
1
.2
4
1
3
6
7
2
.4
3
2
3
7
3
6
.1
2
1
3
8
5
7
.0
0
0
4
9
2
5
.6
7
1
9
1
0
0
3
.7
6
6
7
1
2
0
3
.3
9
0
5
1
2
8
2
.1
3
5
3
1
4
2
8
.2
5
1
7
1
5
8
6
.6
0
7
7
In
te
n
s
it
y
Raman shift(cm-1)
 421
600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800
0
5000
10000
15000
20000
25000
30000
35000
40000
45000
3
8
8
.3
2
3
1
5
5
0
.9
0
3
3
7
2
1
.1
7
3
9
8
2
5
.0
4
7
6
1
0
2
0
.2
3
0
5
1
1
5
9
.4
1
4
8
1
2
1
3
.6
8
0
4
1
2
8
4
.6
2
6
5 1
6
0
6
.6
4
5
9
In
te
n
s
it
y
Raman shift(cm-1)
 470
600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800
0
5000
10000
15000
20000
7
9
5
.6
9
4
3
8
5
1
.1
5
1
4
1
0
2
5
.6
4
6
2
1
0
6
6
.3
7
2
6
1
2
0
6
.0
9
8
4
1
3
3
9
.0
0
0
5
1
6
1
7
.5
8
5
6
1
6
4
3
.9
0
6
1
In
te
n
s
it
y
Raman shift(cm-1)
 440
33 
Figure 3.2: Overlaid spectra showing the peak selected to uniquely identify each particle. 
Here unique peak for 421 particles is at 921 cm-1, 440 particle’s unique peak is at 1335 cm-1, 
470 particle’s unique peak is at 1159 cm-1, and 420 particle is 1077cm-1. 
Overlaying of each particle gives clear indication of choosing best mixtures. Combination of 
420, 421, 440 or 421, 440, 470 can be good candidates for multiplexing assay. Therefore two 
best mixtures (420, 421, 440 and 421, 440, 470) were prepared separately in eppendorf and 
spread as a line on a lateral flow strip for analysis. Results are shown in Figure 3.3 for the 
selected particles mixture. 
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Figure 3.3:  Spectrum of 2 best mixtures shows particles unique peak. (Left) 421, 420 and 
470 unique peaks and (right) 421, 470 and 440 unique peak. 
 
Two best mixtures of particles analysis showed that deconvolution of the 2nd mixture (421, 
440 and 470) spectrum is clear and each particles unique peak is well separated. While in a 
first mixture 420 and 440 particles peaks were very close to each other and may interfere 
with each other for complex assay. Therefore, for the multiplexing assay the selected 
combination of 421, 440 and 470 particles will be used and tested for the relevant analyte. 
3.2 Calibration of SERS particles in suspension   
Aqueous suspension of the SERS particles were serially diluted and measured to obtain 
preliminary calibration plots, Figures.3.4 to 3.7. 
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Figure 3.4: Calibration plot for Oxonica SERS 420 particles in aqueous suspension. Raman 
peak at 1077 cm-1 measured as a function of particle concentration. 
 
Figure 3.5: Calibration plot for Oxonica SERS 421 particles in aqueous suspension. Raman 
peak at 921 cm-1 measured as a function of particle concentration. 
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Figure 3.6: Calibration plot for Oxonica SERS 440 particles in aqueous suspension. Raman 
peak at 1335 cm-1 measured as a function of particle concentration. 
 
Figure 3.7: Calibration plot for Oxonica SERS 470 particles in aqueous suspension. Raman 
peak at 1159 cm-1 measured as a function of particle concentration. 
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The results show that there is a roughly linear relationship between the signal intensity and 
the concentration of particles in suspension: 
3.3 Various scanning technique for lateral flow strip on Raman reader 
Results of two different scanning techniques were conducted in duplicates and plotted 
below as Figure 3.8 using SERS 420 particles. Figure 3.8 show that 3 point scanning method 
doesn’t give a definite response for below 0.2 % SERS particles. The average intensity of 
each SERS concentration is half then Y-axis scan. In summary, peak intensity and peak area 
of Y axis scan is clear, higher and more promising than 3 point measurement on the test line 
for each SERS particles concentration.  
 
420 = (8.78E-08±6.39E-09) * [SERS 420 /ml -1] + (1396  ±1095) (A) 
 
421 = (5.12E-08 ± 1.43E-09) * [SERS 421 /ml -1] + (324  ± 246) (B) 
 
440 = (5.96E-08 ±2.21E-09) * [SERS 440 /ml -1] + (521 ± 378) (C) 
 
470 = (1.55E-07±7.99E-09) * [SERS 470 /ml -1]  + (1608 ±1369) (D) 
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Figure 3.8: Evaluation of scanning method for measurement of SERS 420 particles on a 
lateral flow strip.      Three point scan ■ Y axis scan 
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3.4 UV-Vis analysis results 
All single SERS particles sequential dilution was performed in water. And each sample was 
measured on UV-Vis. Particle absorbance was plotted against their concentration and 
results are shown Figure 3.9 and Table 3.1. UV-Vis results show that all SERS particles give 
linear relationship between absorbance and their subsequent dilution. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9: Absorbance of SERS particles as a function of particle concentration in aqueous 
solution. SERS particle: (♦) 420; (■) 421; (▲) 440; and (x) 470. Absorbance measured at 542 
nm. 
Table 3.1: Absorbance of SERS particles as a function of particle concentration in aqueous 
solution. Absorbance measured at 542 nm.  
SERS Dilution  
particles 
concentration/ml-1 420 421 440 470 
10 1.29E+11 2.415544 2.328781 2.289499 2.41437 
33.3 39000000000 0.67276 0.646474 0.649262 0.674413 
100 12900000000 0.184764 0.197418 0.171646 0.176693 
333.3 3900000000 0.004379 0.005018 0.012859 0.007801 
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3.5 DLS (Dynamic light scattering) results 
Size distribution measurements were performed on the single SERS particles and SERS 
antibody conjugates to optimise protein-loading on the surface using dynamic light 
scattering (Figure 3.10 to 3.13). Here intensity and volume graphs consist of a number of 
logarithm spaced size classes on the x-axis with the percentage of the light scattered 
through the relevant particles in intensity on y-axis or the volume they occupy on y-axis. 
Each particle shows one peak which explains the mono disparity of the particles. The 
presences of additional peaks were not detected indicating the absence of aggregate in the 
solution. Similarly, (Figure 3.14 to 3.17) the results of different combination of three 
selected particles (421, 440 and 470) for the further study show single peaks at ≈165-175 
without showing any aggregation. Also results of these 3 selected particles conjugate 
(troponin - 470, myoglobin - 440 and CRP - 421) mixture was obtained by DLS and plotted in 
Figure 3.18. This confirms the presence of antibody in a mixture by increased size by ≈35-
40nm. All measured size was in triplicates and their mean has been recorded in Table 3.2. 
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Figure 3.10: Dynamic light scattering measurements of SERS 470 particles. (Top) Naked 
particles - without antibody. (Bottom) SERS particles conjugated to troponin antibody. 
Measurements recorded in triplicate. Particles suspended in H2O. 
 
 
 
 
 
 
 
Z-average 
178.7 
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Figure 3.11: Dynamic light scattering measurements of SERS 440 particles. (Top) Naked 
particles - without antibody. (Bottom) SERS particles conjugated to myoglobin antibody. 
Measurements recorded in triplicate. Particles suspended in H2O. 
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Figure 3.5i and 3.5j: 421 SERS size distribution by volume and intensity.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12: Dynamic light scattering measurements of SERS 421 particles. (Top)  Naked 
particles - without antibody.  (Bottom) SERS particles conjugated to CRP antibody. 
Measurements recorded in triplicate. Particles suspended in H20. 
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Figure 3.13: Dynamic light scattering measurements of SERS 420 particles. Only naked 
particles - without antibody.  
 
 
Figure 3.14: Dynamic light scattering measurements of binary mixture of SERS 421 (50%) 
and 440 (50%) particles. Measurements recorded in triplicate. All necked particles mixture 
suspended in H2O. 
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Figure 3.15: Dynamic light scattering measurements of binary mixture of SERS 470 (50%) 
and 440 (50%) particles. Measurements recorded in triplicate. All necked particles mixture 
suspended in H20. 
 
Figure 3.16: Dynamic light scattering measurements of binary mixture of SERS 421 (50%) 
and 470 (50%) particles. Measurements recorded in triplicate. All necked particles mixture 
suspended in H2O. 
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Figure 3.17: Dynamic light scattering measurements of ternary mixture of SERS 421 (33%), 
SERS 470 (33%) and 440 (33%) particles. Measurements recorded in triplicate. All necked 
particles mixture suspended in H2O. 
Figure 3.18: Dynamic light scattering measurements of ternary mixture and antibody 
conjugates (SERS 421-CRP, SERS 470-troponin and 440-myoglobin). Measurements recorded 
in triplicate. All necked particles mixture suspended in H2O. 
 
Table 3.2 lists the mean Z-average (size in diameter) and PdI (polydispersity index) values 
measured for each sample. The data shows that the SERS particles are predominately 
monodisperse with an average size of 161 nm to 178 nm. The selected mixture is also with 
the average size of 164-176 nm. The presences of additional peaks were not detected and 
polydispersity index for each suspension is below 1 that indicating the absence of 
aggregates in the suspensions. 
 
0
5
10
15
20
25
30
10 100 1000
V
o
lu
m
e
(%
) 
Size(d.nm) 
421_440_470_0.3_0.3_0.3 1
421_440_470_0.3_0.3_0.3 2
421_440_470_0.3_0.3_0.3 3
Z-average 
164 
0
5
10
15
20
25
30
10 100 1000
In
te
n
s
it
y
(%
) 
Size(d.nm) 
421_440_470_0.3_0.3_0.3 1
421_440_470_0.3_0.3_0.3 2
421_440_470_0.3_0.3_0.3 3
47 
Sample No Sample ID 
Mean Z-Average 
(diameter.nm) 
Mean PdI 
(polydispersity 
index) 
1 421 169.7 0.027 
2 421 with CRP antibody(conjugated) 186.1 0.007 
3 440 167.5 0.017 
4 440 with myoglobin 
antibody(conjugated) 
209.1 0.163 
5 470 178.7 0.022 
6 470 With troponin 
antibody(conjugated) 
206.9 0.114 
7 420 161.7 0.016 
8 421_440_470(0.5_0.5_0) 168.5 0.013 
9 421_440_470(0_0.5_0.5) 173.3 0.011 
10 421_440_470(0.5_0_0.5) 175.1 0.013 
11 421_440_470(0.3_0.3_0.3) 164.0 0.021 
12 Mixture conjugate(470+440+421) 203.1 0.120 
Table 3.2: Mean Z-Average and PdI values for the single SERS particles before and after 
conjugation. Data is an average of three scans. 
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3.6 Conjugates optimisation 
3.6.1 Buffer optimization 
In order to identify the most suitable buffer and pH without aggregation troponin 
conjugates were prepared in borate, phosphate and acetate buffers pH 6.5, 7.2 and 7.5, 
Figure 3.19 shows the visual identification of aggregation and results are recorded in Table 
3.3.  
 
Figure 3.19: Troponin conjugates prepared in four different buffers with different pH   
values: 6.5, 7.2 and 7.5. 
Buffer:  (1-3) sodium borate; (4-6) sodium phosphate; (7-9) sodium acetate; and (10-12) 
phosphate buffered saline. Buffers diluted ten times in relevant storage buffer to visually 
identify the aggregation, and recorded in Table 3.3. No aggregation observed in 1, 2 and 3, 
10 and 11, while in rest of them aggregation observed visually. 
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Tube no Conjugate buffer Visual results 
   
1 sodium borate pH 6.5   no aggregation 
2 sodium borate pH 7.2     no aggregation 
3 sodium borate pH 7.5 no aggregation 
4 sodium phosphate pH 6.5 aggregations seen 
5 sodium phosphate pH 7.2 aggregations seen 
6 sodium phosphate pH 7.5 aggregations seen 
7 sodium acetate pH 6.5 aggregations seen 
8 sodium acetate pH 7.2 aggregations seen 
9 sodium acetate pH 7.5 aggregations seen 
10 PBS pH 6.5 no aggregation 
11 PBS pH 7.2 no aggregation 
12 PBS pH 7.5 aggregations seen 
Table 3.3: Results of troponin conjugate titrations in different buffer and pH. 
Each conjugate was also run on a lateral flow strip with troponin (to confirm the 
aggregation) and without troponin (to see the non-specific binding on the lateral flow strip. 
Results (Figure 3.20) showed that all conjugates prepared in sodium phosphate, sodium 
acetate and PBS were aggregating. Conjugates prepared in borate did not show aggregation. 
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Figure 3.20: Optimisation of the troponin conjugates activity prepared in four different 
buffers with different pH on a lateral flow strips. No:  (1-3) sodium borate 6.5, 7.2 and 7.5; 
(4-6) sodium phosphate 6.5, 7.2 and 7.5; (7-9) sodium acetate 6.5, 7.2 and 7.5; and (10-12) 
phosphate buffered saline 6.5, 7.2 and 7.5. No 4 to 10 strips shows aggregation of the 
particles at starting of the strip. And among all strip no 2 shows the darkest test line. 
                  
Likewise troponin titration shown above, myoglobin and CRP titrations were performed in 
different buffer and pH and most suitable buffers and pH were selected. For troponin and 
CRP conjugate borate pH 7.2 was the most suitable and for myoglobin borate pH 6.6 was 
the best.  
 
Aggregations 
 
Darkest test line 
 
Control line  
  
Test line  
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3.6.2 Antibody: SMCC ratio optimization 
Five troponin conjugates with different concentration of antibody - sulfo- SMCC were 
examined on lateral flow assay (Figure 3.21). In first 3 set conjugate antibody volumes were 
increased while in set 4 and 5 sulfo-SMCC volumes was decreased (Table 3.4). Troponin strip 
with 1 mg/ml of (540 + MF4) on test line and rabbit anti-mouse 1mg/ml on control line were 
used for the testing of each conjugate set. Figure 3.21 shows each sets are having 8 strips 
where 8 serial dilution of troponin (46, 23.3, 11.6, 5.8, 2.9, 1.5, 0.7, and 0) ng/ml were 
analysed in CRP free serum and mixed with each set of conjugate (15 µl analyte +1 µl 
conjugate). Figure 3.21 confirms that set 3 with antibody loading 810 µg/ml gave the best 
test line colour. While set 1, 2 and 5 were showing aggregations. Particles were crashing at 
the bottom of the lateral flow strips. Set 4 did not show very strong test line in each strip. 
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Figure 3.21: Optimisation of the troponin antibody/SMCC ratio by visualisation on lateral 
flow strips.  
[M19C7] mg/ml: (set 1) 2.4; (set 2) 1.6; (set 3 -5) 0.810. 
[Antibody/SMCC]: (set 1) 85:1; (set 2) 150:1; (set 3) 300:1; (set 4) 68:1; (set 5) 35:1. 
[Troponin] ng/ml: (strip 1) 46; (strip 2) 23.3; (strip 3) 11.61; (strip 4) 5.8; (strip 5) 2.9; (strip 
6) 1.5; (strip 7) 0.7; (strip 8) 0. 
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Detaction Antibody-M19C7 
(mg/ml) 
Sulfo-SMCC 
(mg/ml) 
Ratio 
0.810 2(6.5 µl) 300:01 
1.6 2(6.5 µl) 150:01 
2.4 2(6.5 µl) 80:01 
0.810 2(1.5 µl) 60:01 
0.810 2(3.2 µl) 35:01 
Table 3.4: Troponin Antibody (M19C7) and sulfo -SMCC concentration Table. 
Similarly five myoglobin conjugates were prepared and tested on a strip having myoglobin 
capture antibody-4E2 (1mg/ml) on test line and rabbit anti-mouse 1mg/ml on control line.  
Figure 3.22 shows myoglobin conjugate optimisation results where set 4 with detection 
antibody loading (1.64 mg/ml) shows the darkest test line in all strips. While in sets 1 and 2 
did not appear appropriate test line. Set 3 and 5 had aggregation at the bottom of the strip 
which indicates most of the particles are crashing at the starting point. Table 3.5 shows 
antibody loading on particles in each sets. 
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Figure 3.22: Optimisation of the myoglobin antibody/SMCC ratio by visualisation on lateral 
flow strips.  
[7C3] mg/ml: (set 1, 4 and 5) 1.6; (set 2) 0.810; (set 3 -5) 2.4. 
[Antibody/SMCC]: (set 1) 150:1; (set 2) 300:1; (set 3) 80:1; (set 4) 60:1; (set 5) 30:1. 
[Myoglobin] ng/ml: (strip 1) 500; (strip 2)62.5; (strip 3)7.8; (strip 4) 0.97; (strip 5) 0. 
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Myoglobin Detaction Antibody-
7C3 
 (mg/ml) 
Sulfo-SMCC 
(mg/ml) 
 Ratio 
1.64 2(6.5 µl) 150:01 
0.810 2 (6.5 µl) 300:01 
2.4 2(6.5 µl) 80:01 
1.64 2(2.6 µl) 60:01 
1.64 2(1.5 µl) 35:01 
Table 3.5: Myoglobin detection antibody(7C3) and sulfo -SMCC concentration Table. 
Figure 3.23 shows 6 strips in 4 sets of conjugates were prepared and tested on a lateral flow 
strips. Results shows CRP conjugate optimisation results where set 4 with detection 
antibody loading (1.4 mg/ml) and antibody: SMCC ratio (35:1) showed the darkest test line 
in all strips.  Set 3 had aggregation at the bottom of the strip which indicates most of the 
particles were crashing at the starting point. Table 3.6 represents antibody loading on 
particles in each sets and antibody to SMCC ratio. 
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Figure 3.23: Optimisation of the CRP antibody /SMCC ratio by visualisation on lateral flow 
strips.  
[C6] mg/ml: (set 1) 2.7; (set 2, 3 and 4) 1.4. 
[Antibody/SMCC]: (set 1) 90:1; (set 2) 150:1; (set 3) 60:1; (set 4) 35:1. 
[CRP] ng/ml: (strip 1) 3300; (strip 2) 1100; (strip 3) 370; (strip 4) 110; (strip 5) 0. 
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CRP Detaction  
Antibody-C6 
 (mg/ml) 
Sulfo-SMCC 
(mg/ml) 
Ratio 
2.7  2 (6.5 µl) 90:01 
1.4  2 (6.5 µl) 150:01 
1.4 2 (2.6 µl) 60:01 
1.4 2 (1.5 µl) 35:01 
 
Table 3.6: CRP antibody(C6) and sulfo-SMCC concentration Table. 
 
3.7 Single analyte lateral flow analysis in buffer 
Initially all optimised conjugates were analysed on a single form on lateral flow strips using 
running buffer to confirm that all conjugates dilutions can be analysed on a lateral flow 
strip. Graph 3.24 to 3.26 are the results of each conjugates serial dilution strips analysed 
using the Raman reader and data analysis was performed by combination of Wire and Origin 
software. Each analyte concentrations are plotted on x-axis and their corresponding read 
intensity is on Y-axis. Result shows that different concentration of each analyte can detect 
on lateral flow strip separately. Troponin highest concentration intensity was 80000 RU 
while CRP highest intensity was 30000 RU. Table 3.7 shows all recorded intensity vs. their 
concentration. 
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Figure 3.24: Troponin I assay in simplex format on lateral flow strip. Troponin antibody 
(M19C7) conjugated to SERS 470 particles. Raman intensity read at 1159cm-1 using Y-axis 
scan across the test line. Assay run in running buffer. 
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Figure 3.25: Myoglobin assay in simplex format on lateral flow strip. Myoglobin antibody 
(7C3) conjugated to SERS 440 particles. Raman intensity read at 1335cm-1 using Y-axis scan 
across the test line. Assay run in running buffer. 
 
Figure 3.26:  CRP assay in simplex format on lateral flow strip. CRP antibody (C6) conjugated 
to SERS 421 particles. Raman intensity read at 921cm-1 using Y-axis scan across the test line. 
Assay run in running buffer. 
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60 
Troponin 
concentration 
(ng/ml) 
Intensity  
Myogobin 
concentration 
(ng/ml) 
     
Intensity 
CRP 
concentration 
(ng/ml)  
     
Intensity  
1.4 5201 
- 
- - - 
2.9 5457 6.2 19048.5 63 1874.5 
5.8 9239 12.7 48314.8 125 8742.58 
11.6 20214 25 59021.5 254 14222.8 
23.3 58136 50 90229.4 500 19903 
46.7 65310 100 94341.3 1000 23726.8 
93.5 78086 200 91366.7 2000 20644.2 
187 79208 400 99135.6 4000 30694.4 
Table 3.7:  Troponin, myoglobin and CRP concentration vs. Raman intensity recorded on 
lateral flow strip. 
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3.8 Single analyte lateral flow analysis in serum 
After each conjugate serial dilution analysed in buffer they were analysed in single form on 
lateral flow strips using serum. Figure 3.27 to 3.29 shows analyte concentration vs. their 
intensity observed on a Raman reader. For troponin 100 ng/ml to 0.33 ng/ml has been 
analysed and plotted as figure 3.27. Below Figure 3.28 shows myoglobin can be detected 
using serum from 412 ng/ml to 3 ng/ml .Similarly CRP can be detected on a lateral flow strip 
using serum from 4000 ng/ml to 30 ng/ml. Table 3.8 has the verified intensity of their 
corresponding analyte concentration. Graph shows that all analyte can detect separately 
using serum. 
Figure 3.27: Troponin I assay in simplex format on lateral flow strip using serum. Troponin 
antibody (M19C7) conjugated to SERS 470 particles. Raman intensity read at 1159 cm-1 using 
Y-axis scan across the test line. 
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Figure 3.28:  Myoglobin assay in simplex format on lateral flow strip using serum. Myoglobin 
antibody (7C3) conjugated to SERS 440 particles. Raman intensity read at 1335 cm-1 using Y-
axis scan across the test line. 
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Figure 3.29:  CRP assay in simplex format on lateral flow strip using serum. CRP antibody 
(C6) conjugated to SERS 421 particles. Raman intensity read at 921 cm-1 using Y-axis scan 
across the test line.  
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Table 3.8:  Troponin, myoglobin and CRP concentration vs. Raman intensity recorded on 
lateral flow strip. 
 
3.9 Discussion  
This chapter was laid out a measurement platform for multiplex analysis by investigating 
various fundamental aspects of the assay using different methodologies. The results of the 
characterisation and selection of the particles, development of the lateral flow scanning 
method, preparation and evaluating the conjugates and their application on single lateral 
flow assay are summarised here. 
SERS 420, 440, 470 and 421 particles obtained from Oxonica were studied individually and in 
mixture using a Raman reader (section 3.1). Examination results of the individual particles 
identified their unique Raman peaks using the Raman system (R-3000 QE infra-red laser, 
Ocean Optics, Dunedin, USA). Unique peaks for the 421, 440, 470 and 420 SERS particles 
were found to be at 921 cm-1, 1335 cm-1, 1159 cm-1 and 1077 cm-1 respectively. These peaks 
Troponin 
concentration 
(ng/ml) 
Intensity  Myogobin 
concentration 
(ng/ml) 
     
Intensity 
CRP 
concentration 
(ng/ml)  
     Intensity  
0.33 17.6 3.2 12903   32     198 
1 163 6.4 21506   64    1335 
3.33 977 12.5 35842   125    4698 
10 2706 25.7 47605   250    7600 
33.3 6877 51.5 68105   500   16240 
100 8264 103 73146   1000   16632 
  206 81567   2000   21455 
  414 84858   4000   22870 
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were well-separated in the overlaid spectra as well. The result of the mixture analysis by the 
Raman reader showed that the combination of SERS particles 421, 440 and 470 displayed 
the most separated Raman peaks. Therefore, this combination of the SERS particles has 
been chosen for the further conjugation process with troponin, myoglobin and CRP 
detection antibodies. Calibration of the SERS particles in aqueous suspension verified that 
the number of particles in the suspension were directly proportional to their observed 
Raman intensity (section 3.2). Characterisation by UV-Vis absorbance at 543 nm confirmed 
that the SERS particles were identical in size (section 3.4). Similarly, DLS acquired the size 
distribution of the particles before and after the antibody loading (section 3.5). DLS analysis 
established the size of the individual and mixed particles between 161 nm to 178 nm. An 
increase in each particle’s size from 17 nm to 40 nm was observed after loading the 
antibody on the surface, which is a typical for successfully conjugated particles. No 
aggregation of SERS particles was observed in individual and mixed form. Thus all 
characterisation analyses concluded that the SERS particles were suitable for the lateral flow 
analysis.  
Two different scanning methods were evaluated: a three point scan and a y-axis scan. The 
results revealed that the Y-axis scanning (linear scan) displayed the maximum Raman signals 
in terms of peak intensity and area (section 3.3). Y-axis scanning method examined the strip 
with a constant velocity that allowed the collection of maximum data from the SERS 
particles bound on test line. This method provided more reproducible, stable and fast 
Raman signals especially for a low concentration of the SERS particles. As a result, all lateral 
flow assays from this point have been performed using Y-axis scan method.   
SERS particle - detection antibody conjugates were titrated in different buffer solutions 
(sodium borate; sodium phosphate; sodium acetate; and phosphate buffered saline) and pH 
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conditions (6.5, 7.2 and 7.5). These conjugates were first visually optimised for aggregation 
and then the lateral flow analysis was performed to confirm the bioactivity by colour 
development on the test line (section 3.6.1). This investigation identified the following ideal 
buffer and pH conditions for the preparation of troponin, myoglobin and CRP conjugates: 
Troponin and CRP conjugates in 50 mM sodium borate pH 7.2 showed darkest test line on 
the lateral flow strip without any aggregation. While for myoglobin, 50 mM sodium borate 
pH 6.5 was found to be the most appropriate condition.  
Further optimisation of individual antibody: crosslinker (sulfo - SMCC) ratio for troponin, 
myoglobin and CRP analysis were achieved by visual examination on a lateral flow assay 
(3.6.2). In order to obtain good quality conjugates for troponin, detection antibody /sulfo-
SMCC ratio - 300:1, 150:1, 85:1, 68:1 and 35:1 were analysed and it was found that the 
300:1 ratio provided the maximum binding on the test line. For the optimisation of 
myoglobin, detection antibody / sulfo-SMCC ratio - 300:1, 150:1, 80:1, 60:1 and 30:1 were 
tested and it was found that the conjugate with the 60:1 ratio gave the maximum bioactivity 
on the test line. Similarly, visual optimisation of CRP detection antibody / sulfo-SMCC ratio -
150:1, 90:1, 60:1 and 35:1 were examined and the conjugate with 35:1 ratio was found to 
show the maximum bioactivity on the test line.  
 470 SERS - troponin conjugate with 300:1 (M19C7: sulfo SMCC) ratio in 50 mM sodium 
borate pH 7.2, 440 SERS – myoglobin conjugate with 60:1 (7C3: sulfo SMCC) ratio in 50mM 
sodium borate pH 6.5 and 421 SERS – CRP conjugate with 35:1 (C6: sulfo SMCC) ratio in 50 
mM sodium borate pH 7.2 were prepared to obtain single analyte lateral flow assay in 
buffer and serum. The dose response curve demonstrated that the selected cardiac 
biomarker can be detected approximately to their dynamic ranges, with a well-separated 
Raman intensity for each concentration (section 3.7 and 3.8).  
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In conclusion, this chapter has created a platform for carrying out multiplexed analysis in 
lateral flow set-up by characterising various materials and optimising the assay conditions. 
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CHAPTER 4: Multiplexing lateral flow assay                                                                                                                     
4.0 Introduction 
As mentioned in chapter 1 various studies have demonstrated multiplexing by fluorescence 
and gold nanorods. However, quenching of signals or multiple steps for the detection were 
the major issues in achieving a quantitative assay (Huang et al., 2012; Worsley et al., 2012). 
To overcome these issues this chapter aims to demonstrate the potential of SERS particles in 
the analysis of multiple analytes in a single step. 
The SERS multiplex detection technique was designed as a sandwich assay in which the 
target analyte was bound in between SERS particles labelled with a “detection” antibody 
and a “capture antibody” on the test line. The ratio of signals emitted by the antibodies 
labelled SERS particles revealed the analyte concentration directly in the complex mixture.  
The best combination of the SERS particles and its evaluation with a cardiac biomarker 
antibody on a simplex lateral flow assay using buffer and serum was achieved in the 
previous chapter. The calibration and characterisation analyses have quantified the SERS 
particle and antibody attributes and quantity to be used in the mixture assay. Now, this 
chapter’s focus was to develop a multiplex assay for the chosen cardiac biomarkers on a 
single test line using the optimised conditions identified previously.  
In order to accomplish the target of multiplex detection the following was planned in this 
chapter: (1) Initial multiplexing measurements in serum for all three analytes using 
optimised parameters identified from the simplex lateral flow assay; (2) Refinement of 
multiplexing assay in serum; (3) Effect of high, medium and low concentration of analytes in 
multiplexing and (4) Investigation of interference in multiplexing assay. These are now 
described in detail below. 
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(1) Initial multiplexing assay on lateral flow strip in serum.  
This preliminary examination was intended to ascertain the behaviour of each biomarker in 
a mixture. It also aimed to identify the essential modifications required to acquire well 
separated Raman peak for each analyte in the final multiplex assay. In the designed model 
all capture antibody (MF4+560, 4E2 and C2) were loaded in a mixture on 1 mm test line and 
the best conditions for the preparation of conjugates identified in the previous chapter were 
used to for the initial demonstration of the multiplex assay in serum. Equal amounts of 
conjugates (troponin, myoglobin and CRP) were loaded on the lateral flow strip. All the 
conditions of the multiplex assay were kept same as the simplex assay to make the Raman 
signal intensity obtained in the mixture comparable with the previously obtained individual 
measurement outputs (section 4.1).  
(2) Refinement of multiplexing assay in serum. 
Antibody labelled SERS particles may behave differently in a mixture compared to when 
tested individually. Consequently, this segment was designed to improve the assay 
conditions in mixture until acceptable distinct Raman signals for each sample dilution were 
obtained. Based on the section 4.1 outcomes additional multiplexing assay was conducted 
with increase in particles-detection antibody loading (increased myoglobin and troponin 
conjugate). From the mixture analysis, individual dose-response curves for troponin, 
myoglobin and CRP were obtained according to their individual pathological range in an 
immunoassay (section 4.2). 
(3) Effect of high, medium and low concentration of analytes in multiplexing assay. 
In a disease state, the serum or blood sample may have elevated or negligible biomarkers in 
a blend form (Kelley et al., 2009; McDonnell et al., 2009) and hence this could affect the 
measurements of the targeted biomarker measurements. With this purpose in mind 
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artificial condition were created in serum by adding diverse combination of the biomarkers. 
For example, the effect of a high CRP concentration (1800 ng/ml) with low troponin 
concentration (21 ng/ml) on medium myoglobin concentration (200 ng/ml) was 
investigated.  Twenty seven different combinations of biomarkers were tested (section 4.3).  
(4) Investigation of interference in multiplexing assay: 
The aim of this section was to inspect interference concerns to obtain a qualitative and 
quantitative assay. Thus, following on from the results of section 4.3 this section 
investigated the interference issues in a targeted analyte Raman intensity by discretely 
adding each co-analyte. The examinations were carried out to find out the most effected 
biomarker and the level of interferences. As a result, section 4.4 has examined the 
following: (1) myoglobin and CRP interference on troponin intensity, (2) Troponin and CRP 
interference on myoglobin intensity and (3) troponin and myoglobin interference on CRP 
intensity. 
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4.1 Initial multiplexing assay on lateral flow strip in serum 
An analyte mixture (troponin, myoglobin and CRP) was serially diluted and tested on a 
lateral flow strips. Figure 4.1 to 4.3 and Table 4.1 represent the individual candidate’s 
measured Raman intensity against the corresponding concentration. In all three graphs at 
each concentration other 2 candidates are present. In simple term all analyte intensity were 
deconvoluted and separately plotted in below to understand the assay. Total 7 
concentrations in serial dilution were measured for each candidate and intensity is 
represented in Table 4.1. Compare to single analyte assay from chapter 3 (Figure 3.27) 
troponin shows dissimilar behaviour when it is in mixture form. When it was in single system 
troponin intensity was almost double for most of the concentrations and each 
concentration intensity values were well separated. Figure 4.1 shows that the troponin 
intensity is very poor in multiplexing form. It gives total intensity increase only by 2000 RU 
from lowest (0ng/ml) to highest concentration (65.5ng/ml). Therefore it concludes that 
further assay needs to be done by addition of more troponin conjugate or analyte in the 
assay which may give improvement in the intensity. Similarly compare to Figure 3.28 
myoglobin intensity from multiplex assay (Figure 4.2) is ten times lower. Higher 
concentration (400ng/ml) of myoglobin had the intensity of 15000 RU in presence of other 2 
analyte in high concentration. Figure 4.3 shows CRP behaviour was similar as single analyte 
(Figure 3.29). These results clearly show that myoglobin and troponin assay intensity needs 
improvement in multiplexing form. 
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Figure 4.1: Calibration of troponin assay in serum with multiplex format (using optimised 
simplex parameters). Troponin intensity read at 1159 cm-1 using Y-axis scan across the test 
line.  Optimised simplex parameters: 
[Myoglobin]: 400-6 ng/ml; [CRP]: 4000-60 ng/ml. 
[Myoglobin conjugate]: 0.3 µl/strip; [CRP conjugate]: 0.3 µl/strip. 
Vertical bars indicate +/- standard deviation (n=3). 
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Figure 4.2: Calibration of myoglobin assay in serum with multiplex format (using optimised 
simplex parameters). Myoglobin intensity read at 1335 cm-1 using Y-axis scan across the test 
line.  Optimised simplex parameters: 
[Troponin]: 66-1 ng/ml; [CRP]: 4000-60  ng/ml. 
[Troponin conjugate]: 0.3 µl/strip; [CRP conjugate]: 0.3 µl/strip. 
Vertical bars indicate +/- standard deviation (n=3). 
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Figure 4.3: Calibration of CRP assay in serum with multiplexing format (using optimised 
simplex parameters). CRP intensity read at 921 cm-1 using Y-axis scan across the test line.  
Optimised simplex parameters: 
[Troponin]: 66-1 ng/ml; [Myoglobin]: 400-6 ng/ml. 
[Troponin conjugate]:0.3 µl/strip; [Myoglobin conjugate]: 0.3µl/strip. 
Vertical bars indicate +/- standard deviation (n=3). 
 
Strip 
No 
CRP 
(ng/ml) Intensity 
Troponin 
(ng/ml) Intensity 
Myoglobin 
(ng/ml) Intensity 
1 4000 19551 65.5 4210 400 15253 
2 2000 18680 32.7 3735 200 11391 
3 1000 17001 16.3 3655 100 11266 
4 500 10309 8.18 2988 50 8937 
5 250 6517 4 1376 25 4304 
6 125 3917 2 -729 12 4655 
7 60 3572 1 2203 6 4818 
Table 4.1: CRP, myoglobin and troponin concentration in each multiplex strip and 
corresponding intensity from Raman reader. 
 
In summary, initial multiplexing results were obtained using antibody loading that were 
appropriate in a simplex format but the troponin intensity was very low compare to 
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myoglobin and CRP assay. In addition, the ‘quality’ of the troponin and myoglobin results 
was poor. 
4.2 Multiplexing assay in serum  
In an attempt to improve the multiplexed troponin and myoglobin assays, the loadings of 
troponin and myoglobin conjugates were increased from previous experiment. Sample 
loading method is mention in chapter 2 section 2.5. Here Figure 4.4 to 4.6 represents the 
results for this assay.  
Associate to previous multiplexing attempt (section 4.1) troponin intensities are enhanced 
four times higher and each concentration gives linear response. These results displays that 
by increasing conjugate loading of myoglobin and troponin in the assay, it improves their 
intensity as well. All measured concentration of analyte and their Raman intensity are 
recorded in Table 4.2. 
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Figure 4.4: Calibration of troponin assay in serum with multiplex format (using optimised 
simplex parameters). Troponin intensity read at 1159 cm-1 using Y-axis scan across the test 
line.  Optimised simplex parameters:  
[Myoglobin]: 533-0.7 ng/ml; [CRP]: 5333-7 ng/ml. 
[Myoglobin conjugate]: 0.4 µl/strip; [CRP conjugate]: 0.3 µl/strip. 
Vertical bars indicate +/- standard deviation (n=3). 
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Figure 4.5: Calibration of myoglobin assay in serum with multiplex format (using optimised 
simplex parameters). Myoglobin intensity read at 1335 cm-1 using Y-axis scan across the test 
line.  Optimised simplex parameters: 
[Troponin]: 44-0.06 ng/ml; [CRP]: 5333-7 ng/ml. 
[Troponin conjugate]: 0.4 µl/strip; [CRP conjugate]: 0.3 µl/strip. 
Vertical bars indicate +/- standard deviation (n=3). 
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Figure 4.6: Calibration of CRP assay in serum with multiplex format (using optimised simplex 
parameters). CRP intensity read at 921 cm-1 using Y-axis scan across the test line.  Optimised 
simplex parameters: 
[Troponin]: 44-0.06 ng/ml; [Myoglobin]: 533-0.7 ng/ml. 
[Troponin conjugate]: 0.4 µl/strip; [Myoglobin conjugate]: 0.4 µl/strip. 
Vertical bars indicate +/- standard deviation (n=3). 
 
Strip 
No 
CRP 
(ng/ml) Intensity 
Troponin 
(ng/ml) Intensity 
Myoglobin 
(ng/ml) Intensity 
1 5333 11710 43.7 16636 533 13459 
2 1778 10608 14.6 7909 178 16751 
3 593 6449 4.9 4203 59 10835 
4 198 3887 1.6 3190 20 9031 
5 66 1789 0.6 1666 7 5129 
6 22 822 0.2 1432 2.2 3030 
7 7 26 0.06 -339 0.7 -1726 
Table 4.2: CRP, myoglobin and troponin concentration in each multiplexing strip and 
corresponding intensity read on Raman reader. 
 
Multiplexing assay results shows that all three analyte are separately detectable on 
multiplex format on a single test line of lateral flow strip and their detection range are as 
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below in presence of other two analyte. CRP was detected from 5 ng/ml to 6000 ng/ml; 
troponin was detected from 0.1 ng/ml to 50 ng/ml and myoglobin can be detected from 0.5 
ng/ml to 600 ng/ml. 
4.3 Effect of high, medium and low concentration of analytes in 
multiplexing  
Multiplexing results in section 4.2 showed the detection of all three analytes but it did not 
explain that presence of one analyte in higher or low concentration changing the intensity of 
detection analyte at fix concentration intensity. Therefore, the aim of this work was to 
investigate whether or not the addition of the other two analyte in various concentrations 
would change the analytical signals. CRP, troponin and myoglobin standard curves (Figure 
4.4 to 4.6) were used as a reference and plotted as a red line in below with the 
concentration (■) in graphs (4.7 to 4.9). Three (High, Medium and low) concentration were 
chosen for the examination. Figure 4.7 at selected 3 concentration of troponin (50, 5, 0.4 
ng/ml) when other 2 candidate (CRP and myoglobin) are present in high concentration 
(1800, 178 ng/ml) the troponin intensity is similar to previous assay and represented as (♦). 
When only CRP is loaded in low concentration ((21 ng/ml) and myoglobin was kept high 
((178 ng/ml), that has affected the troponin intensity as well. That is represented as (♦) in 
the graph. Similarly when CRP was kept content as high (1800 ng/ml) and alter myoglobin 
concentration as low (6.5 ng/ml), it again influence in the troponin intensity .that is 
represented as (♦). When both of these candidates (CRP and myoglobin) are present in 
lower concentration (21, 6.5 ng/ml) troponin intensity was increased (♦). Here in all graphs 
only high and low effect is plotted to avoid more complexity .Analogous to troponin graph 
other 2 analyte Figure 4.5 and 4.6 shows the changes in the selected analyte intensity when 
there is a small alteration in the concentration of other candidates present in sample 
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mixture. Each strips and their corresponding concentration of three analytes are 
represented in chapter 2 section 2.11. 
 
Figure 4.7: Effect of myoglobin and CRP on troponin assay at high, medium and low 
concentration. Troponin intensity read at 1159 cm-1 using Y-axis scan across the test line. 
Assay run in serum. 
[CRP] ng/ml: 1800 (♦); 1800 (♦); 21 (♦); 21 (♦) and 0 (■).  
[Myoglobin] ng/ml: 178 (♦); 6.5 (♦); 178(♦); 6.5 (♦) and 0 (■). 
[Troponin conjugate]: 0.4 µl/strip; [Myoglobin conjugate]: 0.4 µl/strip;  
[CRP conjugate]: 0.3 µl/strip. 
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Figure 4.8: Effect of troponin and CRP on myoglobin assay at high, medium and low 
concentration. Myoglobin intensity read at 1335 cm-1 using Y-axis scan across the test line.  
Assay run in serum.   
[CRP] ng/ml: 1800 (♦); 1800 (♦); 21(♦); 21(♦) and 0 (■). 
[Troponin] ng/ml: 50 (♦); 0.54 (♦); 50 (♦); 0.54 (♦) and 0 (■).  
[Troponin conjugate]: 0.4 µl/strip; [Myoglobin conjugate]: 0.4 µl/strip;  
CRP conjugate]: 0.3 µl/strip. 
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Figure 4.9: Effect of troponin and myoglobin on myoglobin assay using revised conditions. 
CRP intensity read at 921 cm-1 using Y-axis scan across the test line. Assay run in serum. 
[Troponin] ng/ml: 50 (♦); 50 (♦); 0.54 (♦); 0.54 (♦) and 0 (■). 
[Myoglobin] ng/ml: 178 (♦); 6.5 (♦); 178 (♦) ; 6.5 (♦) and 0 (■). 
[Troponin conjugate]: 0.4 µl/strip; [Myoglobin conjugate]:0.4 µl/strip;  
[CRP conjugate]: 0.3 µl/strip. 
 
High, low analyte effect assay clearly shows that there are interferences in the assay and it 
need to look further in detail by analysing each candidate separately. Also troponin is most 
effected candidates compared to the others. It also illuminates that these results are 
reproducible by comparing with previous graphs (4.4 to 4.6) but it requires more 
improvements. 
4.4 Investigation of interference in multiplexing assay 
Effect of high, medium and low concentration assay (section 4.3) showed that in mixture 
form present of other two analyte change the intensity of target analyte. So, further assays 
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were undertaken to investigate the effects of the three analytes on each other’s assays 
performance. 
4.4.1 Myoglobin and CRP interference on troponin assay 
 Figures 4.10 to 4.12 shows typical troponin assay curves using multiplexed strips in the 
absences of other two analytes. Similar to previous assay troponin high, medium and low 
concentrations were selected to observe the effects of including CRP in the sample mixture 
(Figure 4.10). The addition of CRP high (3300 ng/ml) effect was grater on high concentration 
of troponin. It reduced the troponin signal (■) by 70%. While CRP low (51 ng/ml) reduced 
troponin signal (■) by ~10% of the total intensity. 
Similarly, Figure 4.11 shows that addition of myoglobin high (540 ng/ml) influence was 
greater on the troponin intensity compare to the addition of low concentration of 
myoglobin (8.4 ng/ml). 
  A Graph 4.12 gives details the effect of CRP and myoglobin together (in mixture form) on 
troponin assay. Again the outcomes show the presence of high CRP (3300 ng/ml) with 
combination of low myoglobin (8.4 ng/ml) or high myoglobin (540 ng/ml) gives the 70% 
signal reduction in troponin high concentration. 
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Figure 4.10: Effect of CRP on troponin assay in serum with multiplex format including both 
myoglobin and CRP conjugates. 
[CRP] ng/ml: (♦) 0; (■) 51 and (■) 3300.  
[Myoglobin] ng/ml: 0. 
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Figure 4.11: Effect of Myoglobin on troponin assay in serum with multiplex format including 
both myoglobin and CRP conjugates. 
 [Myoglobin] ng/ml: (♦) 0; (▲) 8.4 and (▲) 540. 
[CRP] ng/ml: 0. 
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Figure 4.12: Effect of Myoglobin and CRP on troponin assay in serum with multiplex format 
including both myoglobin and CRP conjugates. 
[CRP] ng/ml: (♦) 0; (●) 51and; (●) 3300 and (●) 3300. 
[Myoglobin] ng/ml: (♦) 0; (●) 540 and; (●) 8.4 and (●) 540. 
 
4.4.2 Troponin and CRP interference on myoglobin assay 
Here Figure 4.13 to 4.15 are showing myoglobin typical curve in black line. Likely troponin 
curve this curve doesn’t have other 2 analyte are absence but all conjugate and antibodies 
are present. By adding CRP low (51.5 ng/ml) on troponin assay at high, medium and low 
concentration it shows the reduction in intensity of myoglobin by ≈25%. On addition of high 
CRP (3300 ng/ml), myoglobin intensity is diminish by 50 %  (▲) from the origin (■).Troponin 
high and low concentration effect is lower compare to CRP high effect on myoglobin assay 
(Figure 4.14). 
When CRP and troponin together added in high concentration (●) to the myoglobin assay, 
myoglobin intensity is dropped by 50%. Figure 4.15 shows that when troponin 
concentration is low (2.9 ng/ml) and CRP kept high (3300 ng/ml) myoglobin intensity is still 
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not recovered (▲). On other side When troponin was kept high and CRP was added in low 
concentration, the effect was less but not completely removable (▼). In summary, CRP is 
the most influencing analyte especially when it is added in high (3300 ng/ml) 
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Figure 4.13: Effect of CRP on myoglobin assay in serum with multiplex format including both 
troponin and CRP conjugates. 
[CRP] ng/ml: (▲) 3300; (●) 51 and (■) 0. 
[Troponin] ng/ml: 0. 
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Figure 4.14: Effect of troponin on myoglobin assay in serum with multiplex format including 
both troponin and CRP conjugates. 
[Troponin] ng/ml: (▲) 46.6; (●) 2.9 and (■) 0. 
[CRP] ng/ml: 0. 
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Figure 4.15: Effect of troponin and CRP on myoglobin assay in serum with multiplex format 
including both troponin and CRP conjugates. 
[Troponin] ng/ml:  (■) 0; (▲) 2.9; (●) 46.6 and (▼) 46.6.  
[CRP]  ng/ml: (▲) 3300; (●) 3300 ; (▼) 51 and (■) 0. 
4.4.3 Troponin and myoglobin interference on CRP assay 
Similar to other analytes here CRP curve is plotted in Figure 4.16 to 4.18. First myoglobin 
and troponin effect is observed separately in Figure 4.16 and 4.17. CRP intensity is also 
influenced (Figure 4.16) by adding myoglobin high (540 ng/ml). Addition of low myoglobin 
doesn’t affect much on CRP intensity. Figure 4.17 shows troponin high and low 
concentration don’t change CRP intensity but when it is mixed with myoglobin high and  
added in assay it again decrease the CRP high concentration intensity from 14000RU to 6000 
RU. In overall myoglobin and troponin reduce the CRP signal as other analytes. 
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Figure 4.16: Effect of myoglobin on CRP assay in serum with multiplex format including both 
troponin and myoglobin conjugates. 
[Myoglobin] ng/ml: (●) 540; (▲) 8.4 and (■) 0. 
[Troponin] ng/ml: 0. 
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Figure 4.17: Effect of troponin on CRP assays in serum with multiplex format including both 
troponin and myoglobin conjugates. 
[Troponin] ng/ml: (▲) 2.9; (●) 46.6 and (■) 0. 
[Myoglobin] ng/ml: 0. 
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Figure 4.18: Effect of troponin and myoglobin on CRP assay in serum with multiplex format 
including both troponin and myoglobin conjugates. 
[Troponin] ng/ml: (▲) 2.9; (▼) 2.9; (●) 46.6 and (■) 0.  
[Myoglobin] ng/ml: (▲) 8.4; (▼) 540; (●) 540 and (■) 0. 
 
4.5 Discussion 
To achieve the goal of a successful multiplex assay, the examinations conducted and their 
outcomes are summarised here.  
(1) Initial multiplexing assay on lateral flow strip in serum: 
Initial multiplexed measurements were conducted using similar conditions and antibody 
loadings as in a simplex format. Output Raman signals were deconvoluted to read separate 
Toponin intensity at 1159 cm-1, myoglobin at 1335 cm-1 and CRP at 921 cm-1. Unfortunately, 
the outcomes indicated that the Raman intensity of troponin was very low as compared to 
the myoglobin and CRP intensities. In addition, compared to the single analyte assay 
(section 3.8) the ‘quality of the Raman signal’ of troponin and myoglobin was poorer, i.e. 
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very low intensity was observed for all concentrations in the multiplex assay (section 4.1). 
This output indicated that the three selected analytes are not successfully detected in mixed 
form as they are detected individually. Consequently, the refinement of assay conditions 
was targeted in this chapter. 
(2) Refinement of multiplexing assay in serum:  
Improvement of the multiplexed assay was achieved in section 4.2. In order to gain an 
improved Raman intensity especially for troponin and myoglobin, the assay was performed 
by increasing their conjugate loading of troponin:myoglobin:CRP ratio from 1:1:1 to 
1.5:1.5:1. This modification of the assay made the chosen biomarkers separately detectable 
using multiplex format on a single test line of the lateral flow strip. Each biomarker 
detection range in the presence of co-analytes in serum was as below: CRP was measurable 
from 5 ng/ml to 6000 ng/ml; troponin was measurable from 0.1 ng/ml to 50 ng/ml; and 
myoglobin was measurable from 0.5 ng/ml to 600 ng/ml. 
(3) Effect of high, medium and low concentration of analytes in multiplexing assay: 
Section 4.3 describes the measurements of the effect of high, medium and low 
concentration of co-analyte in the multiplex assay. The results were overlaid on the 
outcomes achieved in section 4.2 to identify the interference effect. However, the results of 
each analyte assay were disappointing when the concentrations of the other two analytes 
were altered in the assay. Targeted analyte intensity was inhibited by the addition of high or 
low concentration of the co-analytes in the assay. Troponin was the most significantly 
affected biomarker of the three. It was also seen that the multiplexing results were 
reproducible by comparing with previously done calibrations in section 4.2.  The inhibition 
effect of co-analytes did not give any specific information about its origin. Nonetheless, it 
highlighted that the interference issues could arise for real disease samples. Hence, 
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individual analyte measurements require thoughtful assessments. To address this issue a 
further investigation was designed. 
(4) Investigation of interference in multiplexing assay: 
 Investigation of the interference issue was carried out for individual analytes in section 4.4. 
Individual analyte curve was obtained on a multiplex strip (all three capture antibodies were 
present) by loading all three conjugates with only targeted analyte.  Then, to identify the 
interference single co-analytes were added in the assay in high, medium and low 
concentration of target analyte. The results showed that CRP interferences on troponin 
Raman intensity were more significant than myoglobin interference. The combined addition 
of CRP and myoglobin showed almost 50% to 60 % signal drop in troponin intensity due to 
the presence of CRP (section 4.4.1).  Similarly, a higher CRP interference was detected on 
myoglobin intensity as compared to the troponin interference. Troponin and CRP impact in 
mixture was visible on myoglobin by the drop of Raman signal by 50 % (section 4.4.2). At 
last, the investigation of CRP intensity showed that the myoglobin interference was twice 
compared to the troponin interference. Troponin and myoglobin mixture effect showed 
almost 60 % decrease in CRP Raman intensity (section 4.4.3). 
In conclusion, this chapter has shown the potential of SERS particles by establishing multiple 
measurements in single test line in serum. However, the quantitative analysis showed the 
challenges of co-analytes’ interferences. Deeper investigations demonstrated that the CRP 
was the most influential candidate for causing interference while troponin was the most 
affected among the three biomarkers. More investigations are needed understand the 
cause of these interferences.  
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CHAPTER 5: Investigation of interference issues  
5.0 Introduction 
The proficiency of the SERS particles to identify individual biomarker from a complex 
mixture was demonstrated in chapter 4 by establishing a multiplex assay. Nevertheless, 
further quantitative examination revealed the challenge of considerable interference of co-
analytes in measurements of the targeted analyte’s Raman signal. The source of the 
interference needs to be identified to eliminate it from the multiplex assay. Therefore, the 
aim of this chapter was to investigate the fundamental cause of the interference problem 
and thus achieve a quantitative assay. Part of this work was undertaken and published with 
colleagues in the Biotechnology department of the National Physical Laboratory. Literature 
review has suggested that interferences in the immunoassay can arise from the various 
sources, like nanoparticles or immunological, depending of the assay design ((b) Davies, 
2005; Kelly et al., 2003). After carefully considering these a number of possible mechanisms 
were identified to inspect the cause of the interference issue:  
(1) Non-specific interactions between co-analytes and antibodies: 
Antigen – antibody reaction plays a central role in lateral flow immunoassay. Thus, to 
develop a robust lateral flow test, the required antibody should be highly specific and 
should have a high affinity for the target antigen. Aggregation of particles, denatured or 
polyclonal antibody or the impurity of the material (antibody or antigen) can result in cross-
reactivity that can be seen as either loss of signal or incorrect signal because of the binding 
of conjugates to the test line in the absence of their specific analyte ((b) Davies, 2005).  Even 
though highly specific (monoclonal) antibody and antigen were purchased for this work but 
still the possibility of cross-reactivity is quite high during the process of conjugation or 
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sample running in mixture. Therefore, it is crucial to examine the non-specific interactions in 
the assay. With this goal in mind, assays were performed to identify the cross-reactivity 
between the target analyte and co-analytes or between their antibodies. Section 5.1 
describes all examined and non-examined but considered mechanisms of the cross-
reactivity.  
(2) “Steric hindrance/crowding” between the SERS nanoparticles on the test line: 
Steric hindrance occurs when a large group of particles inhibit a chemical reaction in a small 
available space by competing with each other. Very few studies have investigated the 
concept of steric hindrances between the particles. Previous examination (section 4.4) had 
showed that when CRP-421 SERS particles were added in high concentration to plot the 
troponin calibration curve, it led the inhibition of troponin Raman intensity. Hence, the 
purpose of this examination was to identify the displacement of the troponin conjugate 
(M19C7- 470 SERS) or blocking of the troponin capture antibody binding site due to the 
presence of CRP in high concentration. To understand this artefact a two-run assay was 
performed using troponin as a model biomarker.  Troponin and CRP/myoglobin assay were 
run one after the other. A scanning electron microscope (SEM) characterisation was carried 
out to investigate the crowding effect or the space on the test line. Therefore, a multiplex 
assay test line with all three analytes at maximum concentrations (troponin 50 µg/L, 
myoglobin 500 µg/L and CRP 50 mg/L) was imaged by SEM to quantify the number of 
particles on the strip. Furthermore, a test-strip with about three time higher concentration 
of anti- mouse antibody - 470 particles was examined by SEM to compare with the multiplex 
strip. The outcomes are presented in section 5.2.  
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(3) Optical Interference: 
Recent articles have investigated the optical properties of the metal nanoparticles including 
calculation of scattering, absorption and excitation efficiencies and their role in biological 
detection (Doering et al., 2007; Kelly et al., 2003; Stuart et al., 2005). Knowledge of the 
extinction coefficient and scattering behaviour of a SERS particle upon the formation of a 
biological over-layer is important for a better understanding of the operation of biosensors. 
Therefore, the purpose of this section was to examine if the high scattering property of the 
gold nanoparticle limits light penetration into the strip and causes the interference. 
To understand the mechanism of the interference between incident laser photons and 
Raman scattered light, the assays were made simple by analysing in duplex form without 
the addition of any antibody or analyte. Therefore, a mixture of 421 and 470 SERS particles 
were deposited on test line to identify the loss of Raman intensity, corresponding to the 
increase in concentration of the second particle (Figure 5.9). To further understand this 
effect, Raman intensity of single (470) SERS particles was monitored after successive 
addition of similarly sized naked gold nanoparticles in the assay. Optical properties of the 
SERS and gold nanoparticles was calculated from Mie theory, the density was measured 
from the SEM images and the concentration was estimated from absorbance at 520 nm to 
identify the optical interference in the output Raman intensity. The observed optical 
interferences and the way to eliminate it from multiplex assay are explained in section 5.3. 
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5.1 Non-specific interactions between co-analytes and antibodies 
In multiplexed assays there is the potential for non-specific interactions between co-
analytes and either or both of the capture and detection antibodies of other analytes.  For 
example, 
Ab2- SERS(sol) + Ab1(im)    


   (Ab2-SERS) Ab1(im) 
and/or 
(A) 
Ag2 Ab2-SERS(sol) + Ab1(im)    


   (Ag2Ab2 –SERS)Ab1(im)  (B) 
Equation:  (A) shows the non-specific interaction between the capture antibody (Ab1) for 
the primary analyte and the detection antibody–SERS particle conjugate in for a co-analyte 
in the absence of the co-analyte. Similarly, (B) shows the non-specific interaction between 
the capture antibody (Ab1) for the primary analyte and the detection antibody- SERS 
conjugate (Ab2-SERS) with co-analyte (Ag2). Where the bracketed terms aq, im and sol 
indicate aqueous, immobilised and sol phases, respectively. 
 
To demonstrate whether or not either of both of these mechanisms were significant in this 
work, assays were carried out using nitrocellulose strips with single analyte capture 
antibodies and run with the two co-analytes (test) and principal analytes (control) using the 
normal test regime (section 2.5). Results are shown in Figure 5.1 and the assay conditions 
are summarised in Table 5.1. 
Tests 1 to 6 in Table 5.1 are equivalent to the simplex assays described in chapter 3 (section 
3.7) and gave the expected results, i.e. in the presence of the target analyte, both the 
control and test lines are positive; while in the absence of the target analyte the test line is 
negative (no signal) and the control line is positive.  Tests 7, 9 and 11 show no (or negligible) 
interaction between co-analyte/antibody conjugates and the analyte capture antibodies 
(equation (B) above).  Tests 8, 10 and 12 show no interaction between capture antibodies 
from the test line to co-analyte detection antibody as above in equation (A). 
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Figure 5.1: Assays to look for non-specific interactions between co-analytes and antibodies. 
Capture antibody (Ab1): (1, 2, 7, 8) CRP; (3, 4, 9, 10) myoglobin; and (5, 6, 11, 12) troponin. 
Antibody conjugate(s) (Ab1-SERS): (1, 2) CRP; (3, 4) myoglobin; (5, 6) troponin; (7, 8) 
myoglobin and troponin; (9, 10) CRP and troponin; (11, 12) CRP and myoglobin.  
Test protein (Agi): (1) CRP; (2, 4, 6, 8, 10, 12) none; (3) myoglobin; (5) troponin; (7) 
myoglobin and troponin; (9) CRP and troponin; and (11) CRP and myoglobin. 
 
There are two other non-specific interaction modes that were not investigated [equations 
(C) and (D)] but, there is no reason to suppose that they are likely to be more significant 
than the interactions that were tested.   
Ag2(aq) + Ab1 – SERS(sol)    


   Ag2Ab1-SERS(sol)   
and/or 
 (C) 
Ag2(aq) + Ab1(im)    


   Ag2Ab1(im)  (D) 
 
All possibilities of non-specific cross reactions (equations A to D) are demonstrated in Table 
5.1 for troponin, myoglobin and CRP. 
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Table 5.1: Assay conditions to look for non-specific interactions between co-analytes and 
antibodies. 
aNo refers to the strip number in Fig. 5.1.  NT indicates ‘not tested’. 
* A positive testline response would be expected if mechanism D was significant. 
** A less intensely positive testline would be expected if mechanism C was significant.  
(NOTE: Conceptually, mechanisms A and B could apply simultaneously in this scenario.) 
 
Capture antibody Testline Mechanism
Ab1(im) Ag1(aq) Ag2(aq) Ab1-SERS(sol) Ab2-SERS(sol) tested
1 CRP CRP - CRP - +'ve -
2 CRP CRP - -'ve -
3 myoglobin myoglobin - myoglobin - +'ve -
4 myoglobin myoglobin - -'ve -
5 troponin troponin - troponin - +'ve -
6 troponin troponin - -'ve -
myoglobin myoglobin
+troponin +troponin
myoglobin
+troponin
CRP CRP
+troponin +troponin
CRP
+troponin
CRP+ CRP
myoglobin +myoglobin
CRP
+myoglobin
NT CRP - myoglobin CRP - * D
NT CRP - troponin CRP - * D
NT myoglobin - CRP myoglobin - * D
NT myoglobin - troponin myoglobin - * D
NT troponin - CRP troponin - * D
NT troponin - myoglobin troponin - * D
NT CRP CRP myoglobin CRP - ** A,B,C
NT CRP CRP troponin CRP - ** A,B,C
NT myoglobin myoglobin CRP myoglobin - ** A,B,C
NT myoglobin myoglobin troponin myoglobin - ** A,B,C
NT troponin troponin CRP troponin - ** A,B,C
NT troponin troponin myoglobin troponin - ** A,B,C
12
B
A
B
A
B
A
Noa
7
8
9
10
11
-'ve
-'ve
-'ve
-'ve
-'ve
-'ve
myoglobin none
nonetroponin
-
-
-
-
-
-
CRP -
-myoglobin
troponin -
CRP
Analyte(s) Conjugate
none
none
none
none
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5.2 “Steric hindrance/crowding” between the SERS nanoparticles on test line 
SERS nanoparticles are ~90-150 nm in diameter. Therefore the possibility of binding 
conjugate particles at the test line is limited by the space available for these large particles. 
Figure 5.2 shows that if more particles (conjugates) are loaded on the test line then there is 
a competition between the particles and they can physically block the access for another 
analytes conjugates to bind on a test line. 
Figure 5.2: Schematic of the SERS  stric effect of lateral flow strip. (Left) large amount of 
SERS partilces coming on test line. (Right ) when they bind on a test line some particles don’t 
have space to attach due to other partilces hindering the space. 
 
Therefore “two run” experiments were structured by running separately each analyte as 
mentioned in chapter 2 (section 2.10) on the same lateral flow strip and observing the signal 
of the first analyte. Troponin was the most affected analyte, therefore it was chosen as a 
model for this assay. Figure 5.3 shows the Raman signal of troponin on the Y axis and the X 
axis are strips A to F. Multiplexing strips were used for this assay. Here strip A is adopted 
from the figure 4.10 to compare with strip B that is having serum as first rum. Strip B shows 
highest intensity; it has serum as a first run and troponin assay as a second run.  It proves 
there is no effect of addition of serum in the assay as a first run. Even strip C is showing 
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similar intensity which had CRP analyte run without conjugate as a 1st run before the 
troponin run on a strip. This indicates no analyte effect on the Raman intensity of troponin 
and no cross reaction between the troponin and CRP antibodies. But when both conjugates 
were mixed and run with the CRP analyte in strip E before the troponin run, it might be 
blocking the binding site of troponin because it reduces the troponin signal by 40%. On strip 
E both assays were run together and troponin intensity was recorded similar to strip D. In 
strip F first run was a serum and second run was a mixture of troponin and CRP, but no 
changes occurred in the result. Troponin intensity from the strip F was recorded similar to 
strip D.  List of the analytes run in the assay are also recorded in figure 5.3. 
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Figure 5.3: CRP interference on troponin intensity using multiplex strip (all captured 
antibodies are present). Troponin intesity was measured at 1159 cm-1 using Y-axis scan 
across the test line. Table includes list of analytes  and conjugates used in strip A to F. 
[CRP] ng/ml: 9900; 
[Troponin] ng/ml: 150; 
[Myoglobin] ng/ml: 0. 
 
Figure 5.4 strip A is also adopted from the figure 4.11 for comparing with serum addition as 
a first run. Strip B shows the exact same intensity as the previous assay. It has the highest 
intensity. It also proves the reproducibility of the assay and no serum effect. Strip C shows 
slightly less intensity which may be because of myoglobin analyte run before running 
Strip Run 1 Run 2 
A Troponin(analyte+ conjugate) Serum 
B Serum Troponin (analyte + conjugate) 
C CRP (analyte) Troponin (analyte + conjugate) 
D CRP (analyte + conjugate) Troponin (analyte + conjugate) 
E CRP (analyte + conjugate) + Troponin (analyte + 
conjugate) 
— 
F Serum CRP (analyte + conjugate) + 
Troponin (analyte + conjugate) 
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troponin assay. Strip D is gives almost half signal compare to strip A and B. That may be due 
to myoglobin blocking the sites on the test line for troponin binding. Troponin signals on 
strip E and F were significantly low where myoglobin and troponin run together before and 
after running serum. These experiments showed the troponin signal is lower after running a 
CRP or myoglobin assay.  
 
Strip Run 1 Run 2 
A Troponin(analyte +conjugate) Serum 
B Serum Troponin (analyte + conjugate) 
C Myoglobin (analyte) Troponin (analyte + conjugate) 
D Myoglobin (analyte + conjugate) Troponin (analyte + conjugate) 
E Myoglobin (analyte + conjugate) +  — 
  Troponin (analyte + conjugate)   
F Serum Myoglobin (analyte + conjugate) + Troponin 
(analyte + conjugate) 
Figure 5.4: Myoglobin interference on troponin intensity using multiplex strip (all captured 
antibodies are present). Troponin intesity was measured at 1159 cm-1 using y-axis scan 
across the test line.Table includes list of analytes  and conjugates used in strip A to F. 
[Myoglobin] ng/ml: 1620; 
[Troponin] ng/ml: 150; 
[CRP] ng/ml: 0. 
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The other evidence by SEM images showed that steric hindrance is not nor the clogging is 
presence on the strip. All high concentration (multiplexed) strips were tested on SEM that 
shows plenty of spaces on the test line for binding more particles. Also in addition to that 
470 particles with anti-mouse antibody on the test-line were tested and shown three fold 
higher particles in the image. These images confirm that number of particles binding to the 
test line does not clog all pores or cover nitrocellulose surface (James et al., 2012).  In 
summary, provided results shows that steric hindrance may not be the cause of 
interference. Figure 5.5 is a pre-test line where no SERS particles are present. Figure 5.6 is 
the test line with all three (troponin, myoglobin and CRP) analytes in highest concentration 
and Figure 5.7 has 470 particles with anti-mouse antibody to access the maximum no of 
capture binding sites. The total no of particles counted by SEM on the strip were threefold 
higher than the no of particle counted on the strip from Figure 5.6. 
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Figure 5.5: Pre-test line of nitrocellulose strip without any SERS particles. Reprinted with 
permission from Noble, J., Attree, S., Horgan, A., Knight, A., Kumarswami, N, Porter, R., and 
Worsley, G. (2012). Optical scattering artifacts observed in the development of multiplexed 
surface enhanced Raman spectroscopy nanotag immunoassays. Anal. Chem. 84, 8246-8252 
Supplementary information.  Copyright 2012 American Chemical Society. 
Nitrocellulose strip 
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Figure 5.6: Test line image of nitrocellulose strip with all three SERS particles in highest 
concentration (CRP 5000 ng/ml, myoglobin 500 ng/ml and troponin 50 ng/ml). 
Reprinted with permission from Noble, J., Attree, S., Horgan, A., Knight, A., Kumarswami, N,, 
Porter, R., and Worsley, G. (2012). Optical scattering artifacts observed in the development 
of multiplexed surface enhanced Raman spectroscopy nanotag immunoassays. Anal. Chem. 
84, 8246-8252 Supplementary information.  Copyright 2012 American Chemical Society. 
 
 
Nitrocellulose strip 
SERS particle 
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Figure 5.7: Test line image of nitrocellulose strip with 470 SERS particles and anti-mouse 
antibody with three time higher compare to the Figure 5.6. 
Reprinted with permission from Noble, J., Attree, S., Horgan, A., Knight, A., Kumarswami, N,, 
Porter, R., and Worsley, G. (2012). Optical scattering artifacts observed in the development 
of multiplexed surface enhanced Raman spectroscopy nanotag immunoassays. Anal. Chem. 
84, 8246-8252 Supplementary information.  Copyright 2012 American Chemical Society. 
 
 
 
 
 
 
 
 
 
 
 
 
Nitrocellulose strip 
SERS particles 
108 
5.3 Optical interference  
The third possibility considered was the effect of light scattering by SERS particles at or near 
the surface of the test line of assay strip that is the closest to illumination source. In this 
case there are many SERS particles (all three analytes at high concentration) at the surface, 
so the amount of scattered light will be large compared to the situation when few particles 
(only one analyte is at high concentration in the mixture) are at or near the surface. 
Consequently there is the possibility that particles in the bulk of the assay strip receive less 
incident photons than expected. This would result in low Raman signal. Figure 5.8 where the 
presence of multiple analytes all at a high concentration in the test line, increases the 
absorption and scattering of the incident and reflected light and resulting in lower optical 
penetration into the lateral flow strip and therefore decreased the signal.  
 
Figure 5.8: Schematic demonstrating the scattering hypothesis. (A) Test line in a 
nitrocellulose strip, expanded right. (B) Multiplex assay strip-where all three analytes are 
present at high concentration, On right (C) Multiplex assay strip -incident photon and 
scattering light when only one analyte presence in high concentration. 
 
This optical scattering artefact is observed in the Multiplexed SERS assay, when all three 
analytes are present in high concentrations and published (Noble et al., 2012). To 
investigate this, 470 and 421 particles were deposited on a lateral flow strip and loss of 
linearity was detected consistent to the increased concentration of the second particles. 
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Figure 5.9 Shows that the addition of the other particles to the assay resulted in the 
decrease in the measured intensity of the first particle. 
 
Figure 5.9:  (Left) 421 SERS particles spotted on nitrocellulose lateral flow strip and imaged. 
By increasing the co-deposition of 470 particles in the assay shows decrease in the Raman 
intensity of 421 particles. (Right) 470 SERS particles spotted on nitrocellulose lateral flow 
strip and imaged. By increasing the co-deposition of 421 particles in the assay shows 
decrease in the Raman intensity of 421 particles. Reprinted with permission from Noble, J., 
Attree, S., Horgan, A., Knight, A., Kumarswami, N., Porter, R., and Worsley, G. (2012). Optical 
scattering artifacts observed in the development of multiplexed surface enhanced Raman 
spectroscopy nanotag immunoassays. Anal. Chem. 84, 8246-8252 Supplementary 
information.  Copyright 2012 American Chemical Society. 
 
 
The above result suggested that the optical density of the SERS particles in the assay is 
causing the interference. For enhanced understanding similar size (at 785nm) of gold 
particles titrated with the fix concentration of SERS 470 and deposited on lateral flow strip. 
SEM was used to count the particles in each test line. Concentrations of gold and SERS were 
measured by absorbance at 520 nm and calculation of optical properties of SERS particles 
was performed using Mie theory calculate software. (Charamisinau et al., 2004; Jain et al., 
2006). Table 5.2 shows that the absorption efficiencies of the particles are relatively low 
(~0.05 and 0.11) but the scattering efficiencies are very high (1.05 and 1.22). Figure 5.10 (a) 
shows that the SERS and gold particles are easily differentiated in the assay using SEM 
image and (b) shows the density of the SERS particle/µm2 of the test line. This was 
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performed to ensure that the addition of the gold particles in to the assay did not alter or 
disturb the density of SERS particles. These strips were analysed by Raman reader and 
plotted as figure 5.11. This suggests that the Raman signal of the SERS particles decreases as 
the addition of gold particles increases in the assay. Results are consistent as observed in 
Figure 5.9 (Noble et al., 2012).  
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Figure 5.10: (a) An SEM image of the test line with mixture of gold and SERS particles. (b) 
The density of SERS particles on the test line with gold particles concentration. The data 
represents the mean, slandered deviation and median of twenty images of the test line. 
Reprinted with permission from Noble, J., Attree, S., Horgan, A., Knight, A., Kumarswami, N,, 
Porter, R., and Worsley, G. (2012). Optical scattering artifacts observed in the development 
of multiplexed surface enhanced Raman spectroscopy nanotag immunoassays. Anal. Chem. 
84, 8246-8252 Supplementary information.  Copyright 2012 American Chemical Society 
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Table 5.2: Scattering, absorption and extinction efficiencies, and molar decadic extinction 
coefficients, for core-shell and naked gold particles.  
Reprinted with permission from Noble, J., Attree, S., Horgan, A., Knight, A., Kumarswami, N,, 
Porter, R., and Worsley, G. (2012). Optical scattering artifacts observed in the development 
of multiplexed surface enhanced Raman spectroscopy nanotag immunoassays. Anal. Chem. 
84, 8246-8252 Supplementary information.  Copyright 2012 
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Figure 5.11: Titrations of SERS particles and Au colloids onto nitrocellulose. 
■ Co-deposited Au colloids: 0 OD 
    Co-deposited Au colloids: 7.5 OD 
    Co-deposited Au colloids: 15 OD 
● Co-deposited Au colloids: 30 OD 
Reprinted with permission from Noble, J., Attree, S., Horgan, A., Knight, A., Kumarswami, N,, 
Porter, R., and Worsley, G. (2012). Optical scattering artifacts observed in the development 
of multiplexed surface enhanced Raman spectroscopy nanotag immunoassays. Anal. Chem. 
84, 8246-8252 Supplementary information.  Copyright 2012 American Chemical Society. 
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5.4 Discussion 
The objective of this chapter was to investigate the cause of the interference in multiplex 
assay observed in chapter 4. Three hypotheses were tested to identify the source of 
interference. Their outcomes are discussed below: 
 
(1) Non-specific interactions between co-analytes and antibodies (Section 5.1):  
As described in section 5.1, (A) cross- reaction between capture antibody of target analyte 
and detection antibody of co-analytes in absence of co-analyte; and (B) cross- reaction 
between capture antibody of target analyte and detection antibody of co-analytes in the 
presence of co-analyte were analysed for troponin, myoglobin and CRP. Analysis of the 
twelve possibilities showed no significant cross-activity between co-analytes or their 
detection antibodies with the targeted capture antibody. However, other cross-reaction 
(equation C and D) were overlooked and could have been investigated (Table 5.1.) Thus, the 
outcome of the first hypothesis didn’t show any significant evidence of immunological 
interference in the assay. 
(2) “Steric hindrance/crowding” between the SERS nanoparticles on test line (Section 5.2):  
A two-run assay with troponin was designed to test the possibility of steric hindrance. A 
small effect of the CRP and myoglobin interferences on troponin intensity was observed. 
Troponin intensity was found to be inhibited when it was run in a mixture with CRP or 
myoglobin. Correspondingly, troponin intensity was slightly inhibited after running CRP or 
myoglobin assay (Figure 5.3 and Figure 5.4). This results hinted clogging on the strip, but the 
SEM images of multiplex strip with highest concentrations ((troponin 50 µg/L, myoglobin 
500 µg/L and CRP 50 mg/L) gave evidence of no clogging on the strip and adequate space 
between the particles was observed on the test line. Additionally, an anti-mouse assay strip 
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with three time higher number of particles was compared with the multiplex strip. To 
summarise, this investigation did not conclude that the steric hindrance was the cause of 
interference in the assay.  
(3) Optical Interference (Section 5.3):  
To understand the issue of interference in multiplex assay, a simpler SERS duplex assay was 
examined using 470 and 421 particles. Raman intensity of 470 particles was found to 
decrease with increase in co-deposition of 421 particles and vice-versa. Optical interference 
effect was also investigated using 470 particles (diameter ~ 140 nm) as a model and titrating 
naked gold particles (diameter ~ 60 nm) in the assay. The Raman intensity of the SERS 
particles was measured in the presence of different concentration of gold-colloid. The 
results showed that Raman intensity from the SERS particles decreased as the concentration 
of gold particles was increased, which is similar to the effect observed in the multiplex 
assay. Nanoparticle concentration was obtained via absorbance measurements at 520 nm. 
Very high scattering efficiencies (1.05 for SERS and 1.22 for gold) and very low absorbance 
efficiencies were observed (0.05 for SERS and 0.11 for gold) from the calculation of optical 
properties using the Mie theory. Furthermore, the plot of SERS intensity of the particles vs. 
their density (measured from SEM images) confirmed the decrease in Raman intensity as 
with the increase in number of particles in the assay (Figure 5.11). Therefore, the optical 
interference effect suggests the use of a reduced number of particles to obtain a 
quantitative assay. However, a possible difficulty in reducing SERS particles in the assay is 
that it would also limit the detection range of troponin and myoglobin. As a result a sample 
with low concentration of biomarkers (i.e. troponin ~ 1 ng/ml or myoglobin ~ 6 mg/ml) may 
not be detected easily using the reduced number of particles. To eliminate the interferences 
a quantitative assay for TNFα or IL6 (inflammation markers) with SERS particles was 
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prepared and directly compared with the fluorescence assay in the attached publication 
(Noble et al., 2012; Worsley, et al., 2012). These assays have used less number of SERS 
particles on lateral flow strips and hence found minimal interferences. A direct comparison 
with fluorescence assay demonstrated that that a semi-quantitative assay with SERS is 
possible for wound healing markers with minimum interferences with detection range 
similar to the fluorescence assay.  
In summary, this chapter have tested all possible sources of interference in the multiplex 
assay. Investigation revealed that the optical density of the SERS particles was the main 
cause of the interference in the measurements. Therefore, to obtain a quantitative assay by 
less number of particles should be used in measurements to eliminate the interference.  
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CHAPTER 6: General Discussion 
6.1 Background and modelling of the assay 
Previous studies have demonstrated the significance of multiple analytes detection in point 
of care (POC) and various established technologies have tried to address this diagnostic 
requirement (Woo et al., 2009; Worsley et al., 2012). However, there have been limitations 
like cost, restriction of detection, interference or necessity of multiple stages for testing 
complex mixtures. This study has been undertaken to explore the potential of SERS particles 
to enable multiplexed immunoassay in lateral flow format (Figure 6.1).  
 
Figure 6.1: Schematic of multiplex assay on a single test line. (a)  Arrangement of lateral flow 
assay incorporating a single test line with capture antibodies (Ab) for each of three target 
antigens (Ag) and respective SERS conjugate (SERS-Ab) preloaded on conjugate pad. (b) 
analytes (Ag) pass through the conjugation pad and bind with their respective SERS 
conjugate. (c) Sample (Ag-SERS-Ab complex) passes onto the test line and makes a sandwich 
assay. Unbound sample with the excess SERS particles moves onto the control line to bind 
with control antibody and rest of the fluid passes toward the absorbance pad. 
[Ag1]: Troponin; [Ag2]: myoglobin; [Ag3]: CRP. 
[SERS-Ab1]: 470-M19C7; [SERS-Ab2]: 440-7C3; [SERS-Ab3]: 421-C6. 
[Capture Ab1]: MF4+560; [Capture Ab2]: 4E2; [Capture Ab3]: C2. 
(a) 
(b) 
(c) 
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The SERS particles (420, 440, 470 and 421) utilised in this research were developed by Oxonica 
LTD (United Kingdom). To establish the concept of multiplex detection, troponin, myoglobin and 
CRP were selected from an extensive background investigation of biomarkers having the utility 
in myocardial Infraction detection. To read the signal from the SERS particles, a Raman System 
R-3000 QE (Ocean Optics, Dunedin, USA) was purchased and modified to work with a lateral 
flow strip holder and stage. Furthermore, a technique (Y-axis scan with 37 mm/s speed) was 
developed to read the real-time quantitative and qualitative signal analysis from the SERS 
particles on the lateral flow strip (Section 3.3). 
First, Raman spectra of the individual commercially obtained SERS particles were obtained using 
the Raman reader. Then the Raman spectra were obtained from a mixture of the SERS particles. 
After the analysis of the individual and mixed Raman spectra, three SERS particles were chosen 
(421, 440 and 470), based on their well-separated unique Raman peaks (921 cm-1, 1335 cm-1 and 
1159 cm-1) to perform the multiplex assay. This was aimed to avoid confusion in distinguishing 
unique features when analysing a diversity of samples. Additionally, a relationship between the 
Raman signal intensity and the concentration of the SERS particles in aqueous solution was 
established using the Raman reader. This relationship was found to be linear (Sections 3.1 and 
3.2).  
From the literature review of this study, techniques like UV-Vis, DLS and lateral flow assay were 
identified for the particles’ characterisation. The examinations of each particle before and after 
conjugation by DLS and UV-Vis spectroscopy confirmed their protein attachment on surface, 
correct size of particles and the lack of aggregation. These results also confirmed the stability of 
the particles after antibody labelling. The antibody labelling on selected SERS particles (421, 440 
and 470) were carried out under different buffer and pH, to select the ideal conditions for the 
assay. The ideal condition for the preparation of conjugates were found to be: (1) Troponin-470 
with 300:1 (M19C7: sulfo SMCC) ratio in 50mM sodium borate pH 7.2; (2) Myoglobin-440 with 
60:1 (7C3: sulfo SMCC) ratio in 50mM sodium borate pH 6.5 and (3) CRP-421 with 35:1 (C6: sulfo 
SMCC) ratio in 50mM sodium borate pH 7.2. Using these conditions a stable single lateral flow 
assays were performed first in buffer and later in serum, across the range of their pathological 
values. These results provided a deep understanding of each candidate’s individual behaviour 
and confirmed their suitability to perform multiplex lateral flow assay (chapter 3). 
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6.2 Multiplex assay 
The principal aim in this study was to develop multiplexing biosensor platform. A first 
multiplexing assay examination was performed using the similar condition for preparing and 
running as they were used in individual analysis. The initial multiplexing assay results showed a 
poor performance of troponin and myoglobin as the Raman signal intensity didn’t change 
significantly with a change in concentration. The intensity of each analyte in the multiplexing 
assay was lower than their individual lateral flow analysis. To improve the Raman signal intensity 
from the analytes an increased SERS particles-antibody was carried out. This enabled each 
analyte to be successfully detected across their pathological values using the Raman reader.  
In summary, the goal of this study was to demonstrate the proof of concept multiplex assay. 
This was shown using a well-established cardiac model system. Each selected analyte and their 
measurable ranges in final single and multiplex assay are summarised here in Table 6.1. Their 
IC50 values have been calculated by sigmoidal logistic fit.  
 
Analytes  
Single analyte assay Multiplex 
assay 
Pathological 
range 
Buffer Serum  serum 
Troponin(ng/ml) 200-1.4 100-0.3 43-0.06 30-0.05 
Measured IC 50 19 15.8 2.3 
 
     Myoglobin(ng/ml) 400-6 415-3 533-0.5 500-5 
Measured IC 50 13.9 19.3 2.2 
 
     CRP(ng/ml) 4000-63 4000-32 5000-7 3000-100 
Measured IC 50 0.57 317 700   
Table 6.1: Summary of each analyte measured ranges and their calculated IC50 values 
compared to their dynamic ranges in single and multiplex assay. 
 
However, interference issues were observed during the further quantitative analysis of the 
multiplexing assay while using high, medium and low concentration of analyte. The results 
showed that an individual analyte’s Raman intensity was inhibited by the addition of co-analytes 
in high concentration. Therefore, individual analyte interference assays were investigated 
separately in the absence or presence of high and low concentrations of co- analytes. Thus, the 
interference challenge was identified at this stage of the study (Chapter 4). 
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6.3 Investigation of interference in the multiplex assay 
The origin of the interference issue was also explored in this study eliminate the inhibition of 
Raman signal in the multiplexing assay. Three possible sources of interference were investigated 
in chapter 5: (1) Non-specific interaction assay – Interaction between the target antibody and 
co-analytes; (2) Steric - effect (crowding effect); (3) Optical interference.  
The output of the non-specific interaction assay test indicated no possibility of cross activity 
between antibodies and co-analytes in the assay.  Investigation of the steric effect using two-run 
assay suggested that the crowding of particles at high concentration might the cause of the 
inhibition of Raman signal because troponin signal was affected after CRP or myglobin assay. But 
SEM images confirmed that there was no crowding on the test line of the multiplexed assay. 
Hence the investigation of the steric-effect did not confirm the cause of the interferences. 
Finally, the investigation of the optical interference was carried out in detail. First, the titration 
of the SERS particles and naked gold particles assay of same size confirmed that the Raman 
intensity of SERS particles was decreasing with the increase in gold particle concentration in the 
assay. This outcome was similar to the observation of the inhibition of Raman intensity observed 
in the previous multiplexing assay. Calculated optical property outcomes of the SERS and gold 
particles showed that the scattering efficiencies were very high and absorbance efficiencies 
were very low. Hence, the observation of the decrease in Raman intensity of the target analyte 
was attributed to increase in the Rayleigh scattering of laser light from the high number of 
particles deposited on the test line. This last interference was analysed within the team at NPL 
and published in Analytical Chemistry (Noble et al., 2012). This examination suggested reducing 
the number of particles used in the assay to eliminate the interference. However, the 
disadvantage of reducing particles concentration in the assay would potentially limit the assay 
sensitivity. Therefore, the SERS assay was demonstrated with reduced particles using wound 
healing biomarkers (TNFα and IL6) showed the minimal interference in the assay.  
 
In conclusion, this study has demonstrated that the main advantage of using SERS particles in 
lateral flow assays is their ability to multiplex. It has been shown that semi-quantitative and 
qualitative multiplexing assays can be performed with a negligible interference using a reduced 
number of particles in the assay. However, a limitation of using SERS particles is that the high 
light scattering from gold nanoparticles limits light penetration into the test line. Therefore, less 
number of particles are recommended to be used in the multiplex assays. 
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6.4 Future research 
A number of assays can be conducted in the future research to improve the technique of 
multiplex immunoassay that has been proposed and demonstrated in this study. Four 
aspects of current methodology seem particularly worthy of a deeper look in the future: 
1. Examination of the cross-reaction modes C and D that have been overlooked in this 
work (section 5.1). In the presence and absence of a specific analyte, the cross-
reaction of the capture antibody and detection antibody with a co-analyte needs to 
be further tested on a lateral flow strip. Therefore, twelve possibilities need to be 
tested as described in section 5.1. Even though, the probability of the cross reaction 
is low, but if any cross-activity is found then further investigation could be carried 
out to eliminate the immunological issues. This further work will support the 
preliminary investigation of the present study and confirm the quality of the 
materials used in current assay.  
2. Investigation of the selected cardiac biomarkers with a reduced number of SERS 
particles (roughly two-four times less) could be conducted. This investigation would 
be expected to eliminate the interferences from the current set-up, which is crucial 
to demonstrate a successful model within the dynamic range of the biomarkers. By 
reducing the number of SERS particles in the assay the limit of detection might arise 
for the lowest concentration of biomarkers (troponin: 0.05 ng/ml and myoglobin: 
5 ng/ml). The sensitivity issue could be resolved by increasing the capture antibody 
concentration (MF4+560, 4E2) on the test line to improve the binding efficiency of 
the conjugate.  
3. Effect of high or low concentration of each capture antibody on test line could be 
analysed in the future. This examination would demonstrate the maximum binding 
efficiency of each analyte on the strip and hence would lead to the improvement of 
the existing model system by increasing the detection range of the analyte. It would 
also confirm the maximum or minimum requirement of the capture antibody in a 
mixture to obtain an improved Raman signal from the test line.  
4. To commercially launch a point of care (POC) biosensor platform with SERS particles 
a few quality control tests of the lateral flow strip need to be performed in addition 
to above analysis. This will include:  
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 Examination of various distances of the test line from the bottom of the strip. 
Currently, the standard distance of the test line is 5 mm from the start of the 
strip. Therefore, testing of 4 mm (closer to the bottom) to 6 mm (far from the 
bottom) distance from the start of the lateral flow strip would be required to 
identify the effect of distance.  
 Testing of various drying times (10 min, 30 min and longer) for the strip after 
running an assay needs to be performed. Both of these quality control tests 
would help to obtain a higher intensity of the Raman signal.  
5. Furthermore, SERS particles can be certainly utilised to detect a range of analytes in 
lateral flow assay in POC, for example, wound healing markers (TNFα, IL6 and 
MMP9) and kidney function biomarkers (serum creatinine, β-Trace protein, cystatin 
C). This will demonstrate the versatility of SERS particles for diagnosis of diverse 
range of diseases in a multiplex format. The attached publication has found that the 
dynamic range of inflammation marker detected by SERS particles is similar to 
fluorescence detection in a duplex format (Noble et al., 2012). However, it would be 
valuable to compare the SERS particles and fluorescence labelling using cardiac 
biomarkers in a multiplex format. This can show the advantages of SERS particles 
over the fluorescence labelling in diagnostic research. 
6. The long-term direction of current concept would be to construct a platform of using 
more (6-9) SERS particles for multiple (6-9) analyte detection by developing a model 
of three test lines on the single lateral flow strip. Currently, there are hardly any 
studies that have addressed or demonstrated this concept. Therefore, this can be a 
very inspirational step in the lateral flow domain, even though many challenges are 
expected to appear in the assay. This model will require two to three capture 
antibodies on one test-line. Hence, 6 - 9 analytes can be detected using three test 
lines (more test line may not fit in a small lateral flow strip). For the success of such a 
model, various steps of analysis would be required for this examination, for example, 
choosing correct biomarker range (with a similar dynamic range), analysing 
combinations of SERS particles, fabrication of three test line with sufficient space to 
avoid interferences, examining capture antibody and detection antibody loading for 
each analyte, investigation of interference as the complexity of assay will increase 
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etc. The success of this concept could launch the routine use of SERS particles in 
diagnostic analyses and herald a novel area of POCT development.  
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